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ABSTRACT
A note to the reader: Portions of this abstract have been previously published in
the journals PLoS One, McGraw et al. 2012. 7(4):e34477, Blood, Basiorka et al.
2011. 118:2382a, and Blood, Basiorka et al. 2012 120(21):3455a, and have been
reproduced here with permissions from the publishers.

Myelodysplastic syndromes (MDS) include a spectrum of stem cell
malignancies characterized by ineffective hematopoiesis and predisposition to
acute myeloid leukemia (AML) transformation. Patients are predominantly older
(greater than 60 years old), with progressive cytopenias resulting from ineffective
and cytologically dysplastic hematopoiesis. MDS subtypes are classified by
morphologic features and bone marrow blast percentage, as well as cytogenetic
pattern, as is the case for deletion 5q MDS. Interstitial deletion of the long arm of
chromosome 5, del(5q), is the most common chromosomal abnormality in
patients with MDS, and the 5q- syndrome, represents a distinct subset of del(5q)
MDS characterized by an isolated deletion, megakaryocyte dysplasia,
hypoplastic anemia, and an indolent natural history. MDS risk stratification is
most commonly based on the International Prognostic Scoring System (IPSS)
with survival outcomes ranging from a few months to many years based on risk
factors. There are several therapeutic options for MDS including hematopoietic
growth factors, immunosuppressive therapy, azanucleosides, and allogeneic
stem cell transplant, however, there is still a need for more effective treatment
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options, particularly targeted therapeutics. One of the most effective treatments
for MDS is selective for del(5q) MDS, and is the second generation
immunomodulatory agent, lenalidomide (LEN).
LEN is an analog of the known teratogen, thalidomide, and has broad
biological effects including selective cytotoxicity to del(5q) clones, activation of Tcells, and expansion of erythroid precursors. In patients with del(5q) MDS, LEN
is effective in up to 75% of patients, however, 50% of patients will become
resistant within 2-3 years of treatment response. Studies in normal
hematopoietic progenitors have shown that LEN induces expansion of the
primitive erythroid precursors, which our laboratory has shown is accompanied
by sensitization of progenitors to ligand induced erythropoietin receptor (EpoR)
signaling. This sensitization is evidenced by increased and prolonged activation
of the Signal Transducer and Activator of Transcription 5 (STAT5), compared to
Epo stimulation alone. Although EpoR signaling is augmented by LEN, the exact
mechanisms by which this is mediated to result in erythroid expansion are not
fully characterized. In del(5q) MDS, we have shown that LEN selectively
suppresses del(5q) clones via inhibition of the haploinsufficient phosphatases
Cdc25c and PP2a, as well as stabilizing the human homolog of the murine
double minute-2 protein (MDM2) to decrease expression of the tumor suppressor,
p53, however, the mechanisms of action of LEN in non-del(5q) MDS remains
elusive.
Although most anemic MDS patients have normal or elevated endogenous
levels of Epo, as well as comparable levels of progenitor EpoR density relative to
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healthy individuals, the biologic pathology underlying the impaired EpoR
signaling in MDS is poorly defined. Recent reports have shown that membrane
microdomains are important for T-cell, c-kit, and integrin signaling, however,
there have been no reports on EpoR membrane localization. Lipid rafts are
discrete membrane entities that provide platforms by which receptors aggregate
and initiate downstream signaling. Furthermore, reports have indicated that
there is a decrease in lipid raft density in GM-CSF primed MDS neutrophils, that
consequently impaired production of reactive oxygen species (ROS) after fMLP
stimulation, suggesting a role of rafts in MDS disease biology. Based on the role
of rafts in signaling, and potential role in MDS pathogenesis, we sought to
determine whether there was specific membrane localization of EpoR to the raft
fractions, and whether disruption of rafts in MDS erythroids could impair EpoR
signaling. To address this, we first examined the membrane localization of EpoR
on the cell surface. We show here that EpoR translocates to lipid rafts in both
erythroid progenitor cell lines as well as primary progenitor cells after stimulation
by Epo. Furthermore, we found that Epo stimulation increases the assembly of
lipid rafts, as well as the aggregation of rafts on the cell surface. Epo stimulation
not only promoted the recruitment of EpoR into the raft fractions, but also
downstream signaling intermediates such as Janus kinase 2 (Jak2), STAT5, and
Lyn kinase. Moreover, a negative regulator of EpoR signaling, the CD45 tyrosine
phosphatase, was redistributed outside of raft fractions after Epo stimulation,
potentially enhancing receptor signal competence. Furthermore, disruption of
lipid rafts by depletion of membrane cholesterol with MβCD (methyl-β-
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cyclodextrin) inhibited EpoR signaling in both cell lines and primary bone marrow
progenitor cells. Additionally, we found that inhibition of Rho-associated, coiledcoil containing protein kinase (ROCK) and/or Ras-related C3 botulinium toxin
substrate 1 (Rac1), blocked the recruitment of the receptor into the raft fractions
indicating a critical role of these GTPases, and associated proteins, in the
transport and localization of EpoR into raft microdomains.
We next asked whether LEN could alter lipid raft assembly in erythroid
precursors in the absence of Epo. LEN not only induced raft formation and
aggregation but also increased F-actin polymerization. Similar to Epo stimulation,
LEN alone was able to induce the recruitment of EpoR, Jak2, and STAT5 into raft
fractions. Additionally, CD45 was redistributed outside of raft fractions after LEN
treatment. Similarly, inhibition of ROCK blocked LEN induced raft formation and
F-actin polymerization, indicating that LEN utilized effectors shared by Epo.
Furthermore, LEN was able to increase raft density in raft deficient primary MDS
erythroid progenitors. These data demonstrate that LEN may enhance erythroid
expansion via induction of EpoR signaling competent raft platforms, to enhance
survival and differentiation transcriptional response.
Recently, ribosomal protein (RP), S-14, gene (RPS14) haplodeficiency
was found to be a key determinant of the hypoplastic anemia in del(5q) MDS.
Allelic loss of RPS14 compromises ribosome assembly, thereby causing
nucleolar stress and release of free RPs that bind to and promote the
degradation of MDM2, the principal negative regulator of p53. As a result, the
accumulation of RPs causes lineage restricted stabilization of p53 in erythroid
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precursors. Our laboratory and colleagues confirmed that cellular p53
expression levels were elevated in del(5q) erythroid precursors, and that LEN
decreased expression in responding patients. However, at the time of LEN
treatment failure, p53 expression was again elevated at levels exceeding those
at baseline. These results suggest that LEN is initially able to reverse p53
accumulation levels and that this action may be a mechanism by which LEN is
selectively cytotoxic to del(5q) clones. Subsequent studies showed that LEN
inhibits the cereblon E3 ubiquitin ligase complex, the newly discovered target of
LEN. Cereblon has been reported to be the principal protein involved in
thalidomide induced teratogenicity. Furthermore, the cytotoxic activity of LEN in
multiple myeloma is dependent on cereblon. Our laboratory found that LEN
inhibits the auto-ubiquitination of MDM2, thereby stabilizing the protein, and
promoting ubiquitination of and ultimately the degradation of p53. Additionally,
we found that LEN blocked the binding of free ribosomal proteins to MDM2,
which are liberated from the nucleosome by ribosomal stress from RPS14
haploinsufficiency, consequently stabilizing the E3-ubiquitin ligase and fostering
p53 degradation.
In non-del(5q) MDS there is no cytotoxicity of MDS clones by LEN,
suggesting an alternative method of erythropoiesis rescue. Although we know
that LEN promotes the formation of signaling platforms, and recruitment of EpoR,
we wished to determine whether there was an effect of LEN on EpoR expression,
as EpoR expression is controlled through ubiquitination and proteasomal
degradation. Treatment of erythroid progenitor cell lines and primary erythroid
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precursors with LEN increased cellular expression of Jak2-associated EpoR in a
concentration dependent manner. There was no change in mRNA expression,
supporting a post transcriptional mechanism. We then investigated whether
receptor up-regulation was limited to EpoR, or included other cytokine receptors.
We found that LEN induced expression of another Jak2 associated Type I
receptor, IL3-R, but did not alter cellular expression of c-kit, a Type II cytokine
receptor. Because Type I cytokine receptor turnover is regulated by a shared
E3-ubiquitin ligase, and LEN inhibited both MDM2 and cereblon, we evaluated
the effects of LEN on the E3-ubiquitin ligase, Ring Finger Protein-41 (RNF41),
which regulates steady state or ligand independent, Jak2 associated Type I
receptor internalization. We found that LEN inhibited the ubiquitination activity of
RNF41, ultimately stabilizing EpoR membrane residence and increasing
expression.
In summary, MDS patients display ineffective hematopoiesis likely in part
to decreased lipid raft assembly. Stimulation by Epo, or treatment by LEN, not
only induced raft formation, but also induced the recruitment of both growth factor
receptor, and downstream signaling intermediates into raft fractions to enhance
EpoR signal fidelity. We have shown here two methods by which LEN may
augment EpoR signaling. First, LEN increases lipid rafts and promotes
recruitment of signaling effectors. Second, LEN increases and stabilizes the
expression of EpoR through inhibition of the E3 ubiquitin ligase, RNF41.
Therefore, we suggest here that LEN may have broad E3 ubiquitin ligase
inhibitory effects. These data also indicate that lipid raft upregulation by LEN is
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mediated through GTPases, suggesting that GTPase activation may also occur
via inhibition of specific E3 ubiquitin ligases, a question to be addressed in future
studies.
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CHAPTER 1
Background

Myelodysplastic Syndromes (MDS)

MDS Overview. Myelodysplastic syndromes (MDS) are a heterogeneous
group of stem cell disorders characterized by ineffective hematopoiesis and
predisposition to acute myeloid leukemia (AML) transformation. Pathobiological
features of MDS include upregulation of inflammatory response genes and
corresponding cytokine production that contribute to accelerated apoptotic death
of hematopoietic progenitors with consequent ineffective hematopoiesis which
underlies the cytopenias characteristic of MDS.1 MDS is observed primarily in
older individuals (greater than 60y) and overall survival ranges from as short as a
few months to several years based on a number of disease features detailed
below. Although there are instances of familial MDS, these cases are rare and
have been linked to mutations in particular genes such as RUNX1.2 MDS also
occurs in children, although rarely, and is often associated with constitutional
genetic disorders or inherited bone marrow failure syndromes.3 The prevalence
of MDS is greater in males than females, and is observed more frequently in
patients previously exposed to toxic agents, such as chemotherapy or radiation.4

1

Recent reports suggest that there are up to about 75 per 100,000 new MDS
cases diagnosed each year in the US among individuals 65 years of age or
older.5

MDS classification. Distinction of MDS subtypes utilizes the subjective
morphologic characterization of cytological dysplasias that was first defined more
than 30 years ago.6-8 MDS subtypes were initially characterized according to the
French-American-British (FAB) classification for MDS that was developed in
1982.9,10 A diagnosis of MDS by the FAB classification was strictly based on cell
morphology and bone marrow blast percentage; however, considerable
prognostic overlap between subtypes and a surge of data on disease biology
generated the need for a new classification system. In 2001, the World Health
Organization (WHO) established a new classification that further refined
subtypes, reorganized previous classifications, and added additional categories.811

The WHO classification was also based on morphology and blast counts,

however, a single chromosomal aberration, del(5q) was introduced into the
diagnostic criteria. The 2001 WHO classification implemented discrimination
based on the number of lineages of cytological dysplasia and introduced the
RCMD (refractory cytopenia with multilineage dysplasia) subtype, either with or
without ring sideroblasts (RS). The WHO also lowered the blast threshold for
AML from 30% to 20%, and moved chronic myelomonocytic leukemia (CMML)
into a new category of MDS/MPN (myelodysplastic myeloproliferative
neoplasm).8-10,12 Additionally, a new category was added, the 5q- syndrome, a
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subtype characterized by less than 5% bone marrow blasts and an isolated
chromosome 5q deletion.8,12 Detailed discussion of the 5q- syndrome will be
provided in the next section.
Although the 2001 WHO was widely accepted, modest changes were
recommended to this classification system in 2008.8,11,13 The 2008 WHO
classification is still based on cellular morphology, blast percentage, and
cytogenetics, but provides a more detailed subtyping system.8,11 Most notable of
the revisions include reorganization of refractory cytopenias with unilineage
dysplasia (RCUD) into lineage specific subtypes, extension of the description of
MDS-U (unclassified), changing the 5q- syndrome to del(5q) MDS, and addition
of refractory cytopenias of childhood (RCC).8,11-13 Undoubtedly, as new data
emerges and new techniques provide more pathobiologic data, revisions will
likely be needed to further elucidate distinct subtypes of MDS based upon
biological drivers. A summary of the FAB and WHO classifications is provided in
Table 1.

5q- Syndrome. Approximately 50% of patients with MDS carry a
chromosomal abnormality.14,15 The most common chromosomal abnormality
found in up to 25% of MDS patients, is interstitial deletion of part of the long arm
of chromosome 5 [del(5q)].1,16,17 In 1974, Van den Berghe and colleagues first
described this distinct hematological subset of MDS patients and coined the term
5q- syndrome18,19 Patients with 5q- syndrome have severe hypoplastic anemia

3

RCMD

dysplasia in at least 2 lineages, <5% blasts

RCMD
RCMD-RS

21-30% BM blast or presence of Auer rods
monocytosis, up to 20% blast

RAEB-t

CMML
MDS-U

4
MDS-U = MDS unclassified
t-MDS = therapy related MDS

RCUD = refracted cytopenia with unilineage dysplasia
RN = refractory neutopenia
RT = refractory thrombocytopenia
RCC = refractory cytopenia of childhood

RARS = refractory anemia with ringed sideroblasts (RS)

RAEB = refractory anemia with excess blasts

RAEB-t = refracroty anemia with excess blasts with transformation

CMML = chronic myelomonotic leukemia

RCMD = refractory cytopenia with multilineage cytopenia

<5% blasts, dysplasia, pediatrics

RCMD-RS = refractory cytopenia with multilineage cytopenia with ringed sideroblasts

RCC

RA = refractory anemia

10-19% blasts, Auer rods

5-9% blasts, no Auer rods

<5% blasts, megakaryocyte dysplasia, isolated
del(5q)

<5% blasts, dysplasia in less than 10% of any or
multiple lineages

10-19% blasts, Auer rods

5-9% blasts, no Auer rods

dysplasia in at least 2 lineages, <5% blasts

Uinlineage dysplasia, <5% blasts, >15% RS

BM = bone marrow

RAEB-2

RAEB-1

MDS with del(5q)

MDS-U

<5% blasts, dysplasia in less than 10% of any or
multiple lineages

MDS with del(5q)

therapy related

RAEB-2

<5% blasts, megakaryocyte dysplasia, isolated
del(5q)

t-MDS

RAEB-1

dysplasia in at least 2 lineages, <5% blasts, >15%
RS

RARS

cytopenia of at least 2 lineages, BM blast 5-20%

Uinlineage dysplasia, <5% blasts, >15% RS

RAEB

RARS

BM Decription

WHO (2008)

RCUD (RA, RN, RT) Unilineage dysplasia, <5% blasts, <15% RS

Disease

same as RA with >15% RS

Unilineage dysplasia, <5% blasts, <15% RS

BM Decription

RARS

RA

Disease

1 cytopenia, <5% blasts

BM Decription

WHO (2001)

RA

Disease

FAB

Table 1. Comparison of MDS classifications according to the French-AmericanBritish (FAB) and World Health Organization (WHO) classifications.

leading to transfusion dependence, accompanied by mild leukopenia, normal or
elevated platelet counts, and atypical bone marrow megakaryocytes. In 2001,
the WHO created a separate MDS subtype called the 5q- syndrome that required
the presence of isolated del(5q) chromosomal abnormality and bone marrow
blasts less than 5%. There is a higher prevalence of the 5q- syndrome in
females compared to males (7:3) and these patients have better predicted overall
survival and decreased risk for leukemic transformation.16,20,21 Nevertheless,
overall prognosis in the 2001 category of 5q- syndrome was heterogeneous
because of the inclusion of atypical cases with thrombocytopenia or neutropenia.
For this reason, the WHO change the terminology to del(5q) MDS in 2008. The
presence of a single cytogenetic abnormality provides the opportunity for
researchers to study the pathogenesis of this one subtype of MDS, an effort often
complicated by the vast heterogeneity of other subtypes. Mapping of the
commonly deleted region (CDR) in the 5q- syndrome revealed an area of 1.5
megabases comprised of 41 genes located at 5q32-33.20,22 Although initial
studies sought the identification of a tumor suppressor gene that could be linked
to disease development, these efforts were unsuccessful. It was only recently
that one specific gene in the CDR, RPS14, has been linked to the pathogenesis
of the hypoplastic anemia found in del(5q) MDS.23 Ebert et al. performed a
series of elaborate knockdown experiments, and showed that only shRNA
knockdown of RPS14 was able to recapitulate the 5q- phenotype, i.e. erythroid
specific proliferative arrest and apoptosis indicating its importance in the
pathobiology of this disease.23 Haploinsufficiency for RPS14 disrupts ribosome
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assembly causing ribosomal stress, and as in congenital ribosomopathies,
activates p53 in erythroid precursors causing hypoplastic anemia. Further
discussion of ribosomopathies and the 5q- syndrome will follow under the
Ribosomopathies section of this manuscript.

International Prognostic Scoring System (IPSS). Although the WHO
classification system takes into account morphological, cytological, and a single
cytogenetic feature, it lacks other key prognostic variables, and for that reason
risk stratification is accomplished primarily through the International Prognostic
Scoring System (IPSS) which was published in 1997.24 The IPSS divides
patients into four distinct categories; low risk, intermediate-I, intermediate-II, and
high risk disease.24-27 Overall survival and AML transformation risk increases
with risk prognostic score and category, with the median survival for untreated
patients with low, Int-1, Int-2, and high risk disease of 5.7, 3.5, 1.2, and 0.4 years,
respectively.12
The IPSS is calculated based on three parameters; bone marrow blast
percentage, number of cytopenias, and karyotype as summarized in Table 2.9,2527

Each parameter is assigned a particular weighted score which are then

summed to give the cumulative score representative of a particular risk category.
The values for each parameter are also provided in Table 2. Although the IPSS
was developed based on a data set of approximately 800 patients from the US,
Europe, and Japan, the large amounts of data generated since 1997 has led
some to believe a revision of the IPSS was necessary.27 In 2012, the revised
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IPSS, IPSS-R, was published by Greenberg and colleagues.24 The IPSS-R was
based on a significantly larger cohort of patients (IPSS, n= 816; IPSS-R, n=7012)
yet still utilized the same three clinical characteristics of the original IPSS,
including number of cytopenias, bone marrow blast percentage, and karyotype.24
The major changes in the revised system include revised bone marrow blast
percentage categories, grading the severity of each cytopenia, expansion of
chromosomal abnormalities captured, and an increase in the diagnostic
parameters taken into account, such as age, serum ferritin, and lactate
dehydrogenase (LDH). Notably, the IPSS-R has 5 risk categories and 5
cytogenetic risk categories as opposed to four and three in the original IPSS,
respectively.24 The IPSS-R was published in September of 2012; however, at
the time of this manuscript, the IPSS is still the most commonly used prognostic
scoring system by clinicians. Although, the IPSS is the most commonly used
system, it should be noted that there are other proposed risk stratification
systems for MDS such as the WHO classification-based Prognostic Scoring
System (WPSS).28 The WPSS takes into account WHO morphologic subtypes
as well as transfusion dependence, and consists of 5 distinct risk categories
including very low, low, intermediate, high and very high risk categories.28,29 The
most notable characteristic of the WPSS is the effectiveness of determining
prognosis at any time point during the disease, allowing for real time treatment
decision making at any time in the disease natural history.27-29 Yet another
scoring model published in 2008, is the MD Anderson Prognostic Scoring System
(MPSS).30,31 A major component of this system is that disease duration and
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Good

0.5

Intermediate

2/3

5-10%

Score Value

1.2

High

>10%

1

0.4

2.5+

HIGH

Cytopenias: Hemoglobin <10g/dL, Neutrophils <1.8k/µL, Platelets <100k/µL

Karyotype

0/1

No. Cytopenias

0

3.5

<5%

5.7

Median Survival (years)

INT-2
1.5-2.0

IPSS in MDS

0.5-1.0

INT-1

BM Blast %

0

Score

LOW

-Y

del(20q)

del(5q)

Normal

Good

abn: abnormality

-Y + 1 abn

del(20q) + 1 abn

del(5q) + 1 abn

1 abn

Intermediate

Karyotype

chr. 7 abn

2+ abn

High

Table 2. International Prognostic Scoring System (IPSS) of MDS

previous therapies are taken into account, however, it does not consider bone
marrow blast percentage (below 30%) or WHO classification.30,31
Although there are several scoring systems available for risk stratification
in MDS, reports continue describing novel prognostic variables. Some such
variables include β2-microglobulin, bone marrow fibrosis, hypoalbuminemia, and
others.32 It should also be noted that some of these systems, in particular the
IPSS, are limited in their effectiveness due to the heterogeneity within each
subgroup, particularly with respect to the high proportion of normal karyotype
assessed by metaphase cytogenetics.33 Currently, new molecular biomarker
approaches are being proposed including use of single nucleotide polymorphism
(SNP) arrays (SNP-A) or exome sequencing to identify very small genetic lesions
not resolved by metaphase cytogenetics.33 It reasons then, that these scoring
systems will continue to evolve to better delineate risk based on biological
features.

MDS treatment. Often the first treatment for management of anemia in
patients with MDS, particularly lower risk MDS, is the use of erythroid stimulating
agents (ESAs) such as recombinant erythropoietin (Epo), either alone or in
combination with granulocyte/macrophage colony stimulating factor (GM-CSF),
or granulocyte colony stimulating factor (G-CSF).4,34 The use of ESAs grew in
popularity in the early nineties; however, response rates were not robust. Initial
reports of erythroid response rates to Epo ranged from about 10-20%.34,35 With
development of response predictive models, the rates of response to Epo have
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risen with proper patient selection, however, they remain relatively low (30-60%)
and differ greatly between studies and institutions.4,36 A relatively new approach
to treating myelodysplastic syndromes is the use of immunosuppressive
therapies (IST) such as cyclosporine, and ATG (anti-thymocyte globulin).4,37,38
These treatments have had greater success inducing effective hematopoiesis in
younger patients with lower risk disease, however, response rates again vary
greatly from center to center.4 Current studies are underway trying to delineate
those patients expected to respond to IST based on CD4/CD8 ratios or other
biomarkers.38
Another class of MDS therapeutics, the azanucleosides, includes two of
the three currently Food and Drug Administration (FDA) approved therapies for
MDS, azacitidine and decitabine.4,37 The azanucleosides are believed to target
the DNA hypermethylation observed in MDS patients. This treatment option is
primarily used in higher risk patients, or those who fail primary therapies. Current
studies are underway testing novel azanucleosides including the use of new
orally available compounds and combination trials.4,37 The third of the FDA
approved drugs for MDS, is lenalidomide (LEN) (Revlimid®, Celgene Corporation,
Summit, NJ). LEN is approved for the treatment of red blood cell transfusion
dependent patients with lower risk MDS and a chromosome 5q deletion.37 It is
the first cytogenetically targeted therapy for MDS and will be discussed in greater
detail in the next section of this manuscript.
The only potentially curative option currently for the treatment of MDS is
allogeneic stem cell transplant (SCT). This is often not an alternative for most
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patients due to advanced age at disease diagnosis, co-morbidities, or lack of a
compatible donor.4 Encouraging though, is the number of clinical trials either
currently ongoing or in preliminary phases on novel targeted approaches to MDS.
Some of these trials include inhibitors of transforming growth factor β (TGF-β), an
inhibitory hematopoietic cytokine family; indoleamine 2,3 dioxygenease (IDO)
inhibitors that abrogate expansion of Treg and myeloid derived suppressor cells
(MDSC); multi-kinase inhibitors that block PI3K and Akt pathways;
aminopeptidase inhibitors which are amino acid recycling regulators; and p53
inhibition, particularly in LEN-resistant del(5q) MDS.37

Immunomodulatory drugs (IMiDs®)

Thalidomide. Thalidomide is a glutamic acid analogue that was
developed in Germany in 1954 (Figure 1).39,40 Thalidomide was approved in
Europe as a sedative and anti-emetic later that decade under relatively lax
regulatory scrutiny.39-41 Minimal animal models were tested, and similarities to
other barbituates led governing boards to conclude its safety as a sedative.42
Unfortunately, only a few years later in 1961, the drug was withdrawn from the
market due to a tragically high number of cases of teratogenicity in newborn
babies.39-41 It has been reported that more than 10,000 children from 46
countries were affected worldwide.41,42 The majority of these cases involved limb
malformations and congenital defects.41 Although the use of thalidomide as a
sedative was encouraging, particularly due to the lack of toxicity recorded after
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Figure 1. Chemical structures of the IMiDs® thalidomide, lenalidomide, and
pomalidomide

overdose, the US FDA never approved the drug due to unanswered concerns
regarding the drug’s safety, particularly with respect to neurotoxicity.39,41
Interestingly, the European animal models used to test the efficacy and safety of
thalidomide included only mice and rodents, however, it was later found that the
teratogenicity of thalidomide is species specific and is restricted to chickens,
rabbits, and humans.42 Even after several decades of research, the exact
mechanisms of the teratogenicity remains unclear, although recent studies
implicate inhibition of the cereblon E3-ubiquitin ligase complex.39,43 Cereblon will
be discussed in further detail under the E3-ubiquitin ligase section of this
manuscript.
A diverse array of biological effects has been attributed to thalidomide.
Some of these include anti-inflammatory activity, T and NK cell activation, and
suppression of tumor necrosis factor α (TNFα) elaboration.41,42,44 These
attributes, as well as others, led thalidomide to be termed the first
immunomodulatory agent (IMiD®) in clinical use. The anti-inflammatory effects
12

were found to be extraordinarily effective for erythema nodosum leprosum (ENL)
and in 1998 the FDA approved the use of thalidomide in ENL patients.40,42,44
Further studies with thalidomide revealed that it was also an effective antiangiogenic agent, a potentially useful attribute for treating cancer.40,42,44 In 2006,
after several successful clinical trials, the FDA approved thalidomide for the
treatment of multiple myeloma (MM).42,44 Although thalidomide is now approved
for the treatment of several conditions, its use is heavily regulated. In order to be
prescribed in the US, patients, physicians, and pharmacists must all be
registered in the System for Thalidomide Education and Prescription Safety
(STEPS) program. This program was created by Celgene (Summit, NJ) in order
to limit both the marketing and the adverse effects of the compound observed
worldwide.42,44

Lenalidomde. Studies of second generation IMiDs® were met with great
optimism over the last decade. These compounds are less toxic and more
potent than their parent compound.44 Lenalidomide (LEN, RevlimidTM, CC-5013)
is the most well studied second generation IMiD® and is structurally similar to
thalidomide with only the addition of an amine group and loss of one carbonyl
group (Figure 1). LEN is up to 50,000 fold more potent than thalidomide as
measured by inhibition of TNF-α, and more effectively suppresses elaboration of
the pro-inflammatory cytokines IL-1β, IL-1, IL-6 and others, while promoting the
production of anti-inflammatory cytokines such as IL-10.42,45,46 Additionally, LEN
also enhances NK cell activity by promoting population expansion, stimulates
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activation of T-cells by increased production of IL-2 and IFN-γ, and is 3 times
more potent than thalidomide in its ability to inhibit angiogenic response.45,46 The
modulation of the immune system by LEN is an intriguing therapeutic option for
solid tumors. Often, these tumors are able to evade the immune system by
escaping activation of CD4+ cytotoxic T-cells and CD8+ helper T-cells.45 LEN
activates both CD4+ and CD8+ cells, as well as hyper-sensitizes the T-cell
receptor (TCR), and thus may be effective at limiting solid tumor burden.45
Tested as both a single agent and in combination in a number of solid
malignancies including melanoma, prostate, pancreatic, thyroid, brain, ovarian
cancer, and others, efficacy in solid tumors is thus far disappointing.45 However,
there are still more than 200 clinical trials ongoing and as the mechanisms of
LEN are uncovered, it is likely that these findings may prove more positive.45
Although, LEN’s activity in solid tumors has not been particularly
encouraging, there is considerable efficacy in hematological malignancies. In
2005, combination treatments of LEN with the steroids prednisone or
dexamethasone, with or without the addition of the proteasomal inhibitor,
bortezomib, or in combination with the standard care chemotherapy, melphalan,
in MM patients received much attention.40,46 These combination therapies were
very successful, in fact, in the Phase II LEN-melphalan-prednisone trial, there
was partial response or better in over 80% of elderly patients newly diagnosed
with MM.40 Additionally, there was almost a 25% complete response rate.40
These data were staggering considering the overall poor success of previous
regimens. In 2006, LEN was approved for the treatment of MM in patients with
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one prior therapy (www.fda.gov). Although these data are particularly hopeful,
perhaps the most successful story of LEN is in the treatment of del(5q) MDS.

Lenalidomide in MDS. In 2005, a clinical study of 43 lower risk MDS
patients, with either no response to Epo or limited suspected benefit was
published by List et al. in the New England Journal of Medicine.6 In this study,
56% of all patients responded with almost half achieving sustained transfusion
independence.6 Perhaps the most intriguing aspect of this study, was the fact
that 83% of the patients with a del(5q) abnormality responded with normalization
of hemaglobin.6 These numbers were shocking as previous therapies for MDS,
particularly del(5q) MDS, had been disappointing. In a follow up study of 148
del(5q) MDS patients, 76% showed reduced need for transfusions, while 67%
became transfusion independent.1 Transfusion independence was accompanied
by cytogenetic improvement suggesting cytotoxicity to the del(5q) clone.1 These
studies prompted the FDA to approve the treatment of LEN in lower risk del(5q)
MDS patients in 2005.46 As exciting as these results were, and continue to be,
the exact mechanisms and direct targets of LEN were, and are, still not clear.
We do, however, know that LEN has specific mechanisms of action that can
account for the biological effects of LEN in non-del(5q) and del(5q) MDS
independently.

Lenalidomide in non-del(5q) MDS. In non-del(5q) MDS, LEN restores
hematopoiesis by expanding the erythroid progenitor population, as well as
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overcoming the diminished Epo induced STAT5 activation in MDS patients
without observed cytotoxicity to the MDS clone.47-49 Although MDS patients have
either comparable or elevated levels of endogenous Epo with no defects in ligand
binding to receptor, activation of STAT5 through the Epo receptor (EpoR) is
diminished compared to normal progenitors.49 LEN augments Epo induced
STAT5 activation and prolongs the duration of activation compared to Epo
stimulation alone, promoting erythroid expansion. Although LEN is able to
rescue ineffective hematopoiesis in non-del(5q) MDS patients, the transfusion
independence response rate for this subset of patients is only about 25%.6 In
2008, Ebert et al. published a gene signature which was predictive for LEN
response in non-del(5q) MDS and found that there was a decrease in a set of
erythroid differentiation genes in patients that responded to LEN.50 Upon LEN
treatment, these genes were upregulated correcting the defective erythroid
differentiation patterns.50 Although this gene signature may provide a good
biomarker to identify the non-del(5q) MDS patients that may respond to LEN,
clinical use of this data has yet to occur. Furthermore, underexpression of these
lineage specific genes may reflect the impairment in EpoR signaling. The
precise mechanism of action of how erythroid expansion, or induction of erythroid
differentiation genes occurs, is not yet fully understood and is addressed in this
study.

Lenalidomide in del(5q) MDS. Response rates in del(5q) MDS are much
more promising but seem to occur via mechanisms that are distinct from that in
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non-del(5q) MDS. There is approximately a 75% transfusion response rate in
lower risk non-del(5q) patients treated with LEN.1 These astonishing findings led
to LEN becoming the first targeted therapy for lower risk del(5q) MDS patients,
approved by the FDA in 2005. It was also observed that responding patients
commonly showed loss of the del(5q) clone after treatment, suggesting direct
cytotoxicity to this clone.1 Selective cytotoxicity of the del(5q) clone was
confirmed by our laboratory with collaborators in 2009.51 We determined that
clonal sensitivity was a result of LEN’s inhibitory effect on two haplodeficient
phosphatases, CDC25c and PP2Acα.51 Both genes are located in the del(5q)
CDR, and when non-del(5q) MDS primary samples were lentivirally infected with
shRNA for either CDC25c and/or PP2A, the cells underwent an apoptotic
response after LEN exposure similar to del(5q) cells.51 We also found the LEN
inhibited the enzymatic activity of CDC25c and PP2Acα, by direct and indirect
actions, respectively.51 These phosphatases are key regulators of the cell cycle,
and in our experiments, LEN induced a G2-M cell cycle arrest in the del(5q)
cells.51 These results were consistent with a previous study showing selective
cytotoxicity of the del(5q) clone to LEN. In that study, the authors proposed the
selective cytotoxicity may involve upregulation of the CDR encoded tumor
suppressor gene, SPARC.52 Upregulation of SPARC by LEN however was not
restricted to del(5q) clones, and therefore appears to be universal drug effect.52
In summary, LEN enhances erythropoiesis in both non-del(5q) and del(5q) MDS,
albeit by two different mechanisms. Erythroid differentiation and expansion is
observed in non-del(5q) patients, whereas, selective cytotoxicity is observed in
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del(5q) patients. Additional findings from our laboratory on the mechanisms of
LEN in del(5q) patients will be discussed E3 ubiquitin ligase section of this
manuscript.

Pomalidomide. Pomalidomide (CC-4047, Actimid, Pomalyst, Celgene
Corporation, Summit, NJ) is a third generation immunomodulatory agent, that
may be even more potent than LEN. Similar to LEN and thalidomide,
pomalidomide suppresses TNF-α, stimulates T-cells, expands NK cell numbers,
and has anti-angiogenic properties. Currently there are several clinical trials
investigating the effects of pomalidomide, particularly in MM.40 The first Phase I
study of pomalidomide in multiple myeloma, showed a reduction in paraprotein in
67% of patients and a complete response in 10% of patients.40 Subsequently,
several Phase II studies were performed testing the efficacy of dexamethasone
and pomalidomide in refractory or relapsed MM. Results were very encouraging
with responses observed in more than 60% of patients.40,53 Perhaps of most
importance, is the effectiveness of pomalidomide/dexamethasone in thalidomide,
LEN, and bortezomib refractory multiple myeloma patients.40,53 In one study,
pomalidomide/dexamethasone treatment was effective in 40% (8/20) of LENrefractory patients, 37% (6/16) of thalidomide refractory patients, and 60% (6/10)
of bortezomib refractory patients as well as 60% (3/5) bortezomib and LEN
refractory patients.53 These surprising results, in combination with several other
clinical studies, led to the FDA accelerated approval of pomalidomide in
refractory myeloma patients on Feb 8, 2013 (www.fda.gov). Currently,
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pomalidomide is also being testing in myeloproliferative neoplasms and in some
solid tumors with efficacy and reporting yet to be concluded.

Ribosomopathies

Overview. In 1999, mutations in ribosomal protein S19 gene (RPS19)
were found to be associated with the disease pathogenesis of Diamond-Blackfan
anemia (DBA).54 Although it may have not been known at the time, this finding
would become the premise for the characterization of a spectrum of disorders
now known as ribosomopathies. Several congenital hypoplastic anemias caused
by mutations of genes or somatic deletion of genes encoding proteins involved in
ribosome biogenesis as in del(5q) MDS, can be broadly categorized as
ribosomopathies.55 In order to understand these diseases, a brief review of
ribosome biogenesis is warranted (Figure 2). The creation of ribosomes is an
energy intensive process that is highly regulated and is vital to both cell growth
and cell division.56 This process involves hundreds of individual steps, 4
ribosomal RNAs (rRNA), at least 80 different ribosomal proteins (RPs), over 150
associated proteins, and an estimated 70 small nucleolar RNAs, as well as the
coordinated effort of RNAses.57,58 Ribosomal DNA is transcribed into a 45S
precursor by RNA polymerase (pol) I.56 This precursor will be spliced into 28S,
18S, and 5.8S rRNAs.56,58 At the same time, RNA pol III is transcribing an
additional 5S subunit. In association with RPs transcribed by RNA pol II, and
other associated proteins, 60S and 40S ribosomal subunits will be formed from
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these precursors, and will be exported to the cytoplasm where they join to form
the mature 80S ribosome (Figure 2).56,58 Ultimately, it is the responsibility of the
ribosome to translate mRNA and manufacture all proteins necessary for the life
of the cell. These process are highly regulated by a stoichiometric relationship
between precursors and mature subunits, and deregulation can have severe
cellular consequences.56
The finding of RPS19 mutations in DBA provided the foundation for the
study of a number of disorders now known as ribosomopathies. Interestingly, the
majority of these disorders involve bone marrow failure associated with
hypoplastic or non-regenerative anemia. DBA is a heterogeneous disorder
characterized by anemia, erythroid failure, congenital abnormalities, and an
increased risk for leukemic transformation.54,56,59 DBA is usually detected early in
life (within the first year) and is a classic bone marrow failure syndrome with
ineffective hematopoiesis and increased apoptosis of progenitors in the bone
marrow compartment.56,59 Mutations in RPS19 occur in approximately 25% of all
DBA patients, and since the original publications, mutations in four other RP
genes have been identified accounting for up to 50% of mutations detected DBA
patients.58,59 RPS19 is one of the RPs involved in the creation of the 40S subunit
from the 18S subunit, and DBA patients harboring either mutations or
haplodeficiency for this gene have decreased levels of the 40S subunit.56
However, the exact mechanisms by which RPS19 causes a defect in 40S
assembly is yet to be clearly defined.56
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Figure 2. Overview of ribosome biogenesis and ribosomopathy. Ribosome
biogenesis and suspected locations of altered biogenesis in ribosomopathies.
Some of the suspected genes involved are provided in italics. (DC) dyskeratosis
congenital, (CHH) cartilage-hair hypoplasia, (TCS) Treacher-Collins syndrome,
(SDS) Shwachman-Diamond syndrome, (DBA) Diamond-Blackfan anemia.

A second bone marrow failure syndrome caused by defects in ribosome
biogenesis is Shwachman-Diamond syndrome (SDS). Nearly all SDS patients
have severe neutropenia and anemia, with pancytopenia is observed in up to
65% of patients.56,57 In SDS, mutations in the SBDS gene are suspected to be
involved in disease pathogenesis. SBDS is also suspected to be involved in 40S
maturation, although the mechanism by which this occurs in humans has yet to
be determined.57 In X-linked dyskeratosis congenital (DC), mutations in DKC1, a

21

gene thought to be involved in the processing and modifications of the 45S
subunit, are suspected to be linked to disease pathogenesis.56,57 Pancytopenia
and severe aplastic anemia is observed in the majority of X-linked DC
patients.56,57 Cartilage hair hypoplasia (CHH), along with several other clinical
features, presents with hypoplastic anemia and is suspected to be caused by
mutations in the RMRP gene, which is important for the RNAse complex and
splicing of the 45S subunit.56,57 Treacher-Collins syndrome (TCS), characterized
by craniofacial abnormalities similar to those observed in DBA, is thought to be
caused by mutations in TOCF1. The TOCF1 gene encodes Treacle which
effects ribosome DNA transcription by binding an RNA pol I transcription
factor.57,58 Collectively, all these syndromes represent classical ribosomopathies
and bone marrow failure, suggesting a critical role for ribosome biogenesis in the
bone marrow compartment.

The 5q- syndrome as a ribosomopathy. In 2008, Ebert et al.
demonstrated that haploinsufficiency for RPS14 was responsible for the
hypoplastic anemia of the 5q- syndrome.23 Although, haploinsufficiency for
CDC25c and PP2Acα has been demonstrated to be responsible for LEN
sensitivity,51 these RPS14 data were the first to describe a pathway singularly
responsible for the pathogenesis of anemia in MDS. The CDR of del(5q) has
been extensively studied, and most research sought to find a tumor suppressor
gene responsible for disease development. These studies were all unsuccessful
at identifying such a gene.20,22 Since no mutations or biallelic deletions have
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ever been identified, Ebert et al. hypothesized that haploinsufficiency may be the
cause of disease phenotype.23 In an effort to test this hypothesis, the
investigators generated a panel of shRNAs targeting the 41 genes contained
within the CDR.23 Each gene was knocked down by approximately 50% in order
to mimic the allelic haploinsufficiency. Partial loss of only RPS14 mimicked a 5qphenotype, which was resolved in RPS14 add back experiments.23 RPS14
knockdown caused proliferative arrest and loss of differentiation of mature
erythroid cells, and ultimately is the cause of hypoplastic anemia in the 5qsyndrome phenotype.23 Although the exact functions of RPS14 are unknown,
knockdown resulted in a decrease in 18S rRNA suggesting aberrant splicing of
precursor RNAs.23 These data were confirmed in a mouse model, where
deletion of all genes in the human CDR including RPS14 recapitulated the
disease.21 In summary, RPS14 haplodeficiency is implicated in del(5q) MDS
pathogenesis, and provides further insight into disease biology.

Phenotypical differences in ribosomopathies. These syndromes all
represent a new class of syndromes known as ribosomopathies, and interestingly,
most are also bone marrow failure syndromes. For the first time, a group of
diseases is recognized by the failure of a cell to effectively produce mature
functioning ribosomes, whether it be due to mutation or haplosufficiency. The
question arises, what causes the distinct phenotypes in each of these diseases,
and why do they seem to be specific or preferential to the bone marrow? The
answer to this is yet to be determined; however, proposed models exist and are
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currently being investigated. According to a review by Ganapathi and
Shimamura, these models are generally as follows, 1) highly proliferative cells
such as erythroid progenitors and/or hematopoietic stem cells are particularly
sensitive to ribosome biogenesis ineffectiveness, 2) specific mRNAs particular to
the bone marrow may be selectively effected, 3) certain tissues may be
selectively sensitive to decreased ribosome biogenesis, 4) cells with high output
of RPs may be selectively sensitive to an accumulation of free RPs in the cell,
and 5) increased cell cycle arrest and/or apoptosis may be particularly
detrimental to hematopoietic stem cells.56 Although, none of these models have
yet to be proven, there is one common theme that may serve to link them, and
describe how aberrations in ribosome biogenesis pathway may cause a number
of phenotypically diverse syndromes. This link is an accumulation of the tumor
suppressor, p53.

Stabilization of P53. The p53 tumor suppressor has a number of cell
regulatory functions including cell cycle and apoptosis. The E3-ubiquitin ligase,
MDM2, is the principal negative regulator of p53 and targets p53 for proteasomal
degradation. Free or unbound RPs are able to bind to MDM2 rendering it unable
to bind to, and ubiquitinate p53, thus leading to the stabilization of p53.60 In
ribosomopathies, disruption of ribosome biogenesis results in nucleolar stress
and the release of free, unbound RPs. These RPs bind to and promote the
degradation of MDM2, thereby stabilizing p53 (Figure 3).60,61 Haploinsufficiency
of RPS14 and RPS19 resulted in erythroid specific accumulation of p53 and
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consequent cell cycle arrest.62 This phenomenon likely accounts for the lack of
mature erythroid cells in both the 5q- syndrome and DBA.62 Interestingly,
inhibition of p53 restored hematopoiesis, while activation by Nutlin-3 also
impaired erythropoiesis.62 Similarly, in Barlow’s et al. syntenic mouse model,
phenotypically similar to the 5q- syndrome, inactivation of p53 was sufficient to
rescue the hematologic phenotype in these animals.21 These findings suggest
that lineage specific stabilization of p53 due to nucleolar stress and excessive
unbound RPs, may account for the phenotypic heterogeneity of bone marrow
failure syndromes and/or ribosomopathies and may be a potential therapeutic
target of these syndromes.

Figure 3. Stabilization of p53 after ribosomal or nucleolar stress observed in
ribosomopathies. Without nucleolar stress, the 40S and 60S with ribosomal
proteins (RP) come together to form mature, functioning ribosomes, and MDM2
is free to bind and ubiquitinate p53. However, under nucleolar stress conditions,
unbound RPs are able to bind to MDM2 preventing its binding to p53 resulting in
stabilization of p53. (rRNA) ribosomal RNA.
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Hematopoiesis

Overview. Hematopoiesis, or the process of mature blood cell production,
is a highly regulated process that in addition to producing the cells needed to
maintain vital functions, is also regulated in times of infection or bleeding and is
often deregulated in hematological malignancies. Hematopoiesis occurs through
an intricate coordination between cytokines and transcription factors.63-65
Although a full description of the complexity of hematopoiesis may very well
encompass this entire manuscript, a brief review is warranted for the following
study. Briefly, hematopoietic stem cells (HSC), capable of both self-renewal and
commitment to all mature blood lineages, differentiate into lineage committed
progenitors which mature into precursors ultimately resulting in blood cells.63-65
Upon particular cytokine stimulation, multipotent HSC will differentiate into either
common lymphoid (CLP) or common myeloid progenitors (CMP).63-65 CLPs will
mature into T-cell and natural killer (NK) cell progenitors, which turn to mature Tand NK cells.63-65 The CLP may also differentiate into a B-cell precursor, and
ultimately mature B-cells.63-65 The CMP will differentiate into mature erythrocytes,
megakaryocytes and platelets, neutrophils, macrophages, basophils, eosinophils,
and mast cells.63-65 The progenitor and differentiating status of primary samples
can be identified in vitro using colony forming capacity (CFA) assays. In CFAs,
primary cells are plated in a semi-solid medium supplemented with appropriate
cytokines, and after 14 days, colony types, or progenitor potential, may be
determined based on the different morphological characteristics of the
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colonies.66,67 Colony forming units-granulocyte, erythroid, macrophage,
megakaryocyte (CFU-GEMM) is a mixed lineage progenitor that differentiates
into CFU-granulocyte, macrophage progenitors (CFU-GM), as well as the burst
forming unit-erythroid (BFU-E).66,67 BFU-E are the most primitive of the erythroid
progenitors and are dependent on the growth factor, erythropoietin (Epo), for
maturation.66,67 BFU-E will differentiate into CFU-E which are also dependent on
Epo for maturation, and will eventually complete terminal maturation into
erythrocytes.66,67 The maturation and proliferation of the erythroid lineage is also
dependent on the transcription factor, GATA-1.63 A decrease in GATA-1
expression in a mouse model resulted in a decrease in erythroid precursors.65 A
thorough review of the erythropoietin receptor signaling pathway and the
transcription factors involved in erythropoiesis will be provided under
Erythropoietin Receptor Signaling. An overview of hematopoietic differentiation
is represented in Figure 4.

Hematopoiesis in MDS. A hallmark of all bone marrow failure
syndromes is ineffective hematopoiesis. Erythropoiesis is often highly disrupted
in MDS despite comparative levels of the EpoR, and similar or elevated levels of
endogenous Epo in MDS patients compared to normal controls.49 In the case of
del(5q) MDS, defective erythropoiesis is caused by allelic haploinsufficiency for
the RPS14 gene product and consequent lineage specific stabilization of p53.23,62
Alternatively, in non-del(5q) MDS, there are several factors contributing to
ineffective hematopoiesis and erythropoiesis.68 Kitagawa et al. demonstrated
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Figure 4. Hematopoiesis. The hematopoietic stem cell (HSC) may differentiate
into either common lymphoid or common myeloid progenitors (CLP or CMP).
The CLP produces all mature T-, B-, and NK cells, while the CMP will
differentiate into all other blood cell types. The colony forming unit-granulocyte,
erythroid, macrophage, megakaryocyte (CFU-GEMM), matures into CFUgranulocyte, macrophage progenitors (CFU-GM) that will mature to neutrophils
and macrophages, as well as the burst forming unit-erythorid (BFU-E), and
colony forming unit-erythroid (CFU-E), that will eventually evolve into mature
ertyhrocytes.

that bone marrow macrophages from MDS patients express higher levels of
tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ), inhibitory
hematopoietic cytokines, compared to normal primary cells.69 An increase in
these cytokines suppresses maturation and differentiation in normal
hematopoietic progenitors, and is implicated in the observed cytopenias in
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MDS.69 These inflammatory cytokines also induce surface membrane
expression of the death receptor, Fas, and its ligand, Fas-L, in erythroids
enabling lineage specific apoptosis.70 Alternatively, defective hematopoiesis in
MDS may also relate to epigenetic silencing of genes critical to cell growth and
maturation.68,71-73 Aberrant promoter methylation of genes involved in cell cycle
regulation, differentiation, and apoptosis.68,71-73 Hypermethylation of key
regulatory genes leading to gene silencing and decreased expression of proteins
such as survivin, CHK2, and WT1, lowers cellular threshold for apoptosis in early
progenitors thereby accelerating the loss of maturing erythroid cells.68,71 Wei et
al. used a CHIP-Seq analysis in CD34+ cells isolated from MDS patients to
identify hypermethylation involving 36 genes, the majority of which were involved
in NF-κB activation and innate immunity.72 Del Rey and colleagues showed that
hypermethylation silencing key genes involved in cell survival, i.e. Bcl2 and
ETS.73 Del Rey et al. also showed aberrant innate immune response due to
hypermethylation and silencing of IL27RA and DICER1, regulators of microRNA
biogenesis.73 Additionally, effectors of DNA methylation such as DNA
methyltransferase (DNMT)-3a and 3b, were found to be increased in higher risk
MDS patients compared to lower risk patients and normal controls, providing
further evidence that gene methylation and epigenetic gene silencing in general
may be important in the pathogenesis of the disease.71 These findings provided
the basis for 2 of the 3 of the drugs currently approved by the FDA for MDS, 5azacitidine (azacitidine, Vidaza®) and 5-aza-2’-deoxycitidine (decitabine,
Dacogen®).74,75 These azanucleosides were shown to have in vivo
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demethylating properties and improve hematopoiesis as evidenced by
hematologic improvement in 30-50% of MDS patients.74,75
In the following investigations, focus will be placed on ineffective
erythropoiesis in MDS, particularly as it relates to Epo initiated signal response in
MDS progenitors.

Erythropoietin Receptor Signaling

Erythropoietin. Erythropoietin (Epo) is a 34kD glycoprotein hormone that
is responsible for red blood cell (RBC) survival, proliferation, and
differentiation.70,76-78 The Epo gene was cloned in 1985 following delineation of
gene location and subsequent functional analysis.70,76-79 Epo is primarily
produced in the kidney with about 20% production from the liver in adults.77,79
The Epo gene is transcriptionally regulated and is activated in times of hypoxia or
bleeding, in addition to balancing the basal level of mature erythrocyte mass.11
Recombinant human Epo (rhEpo) has been used to treat the anemia in
conditions of endogenous hormone production such as renal failure and in
acquired immunodeficiency syndrome (AIDS), as well as in patients with a variety
of causes of anemia such as that related to chemotherapy, and in patients with
MDS.70,76,77,79 In each of these cases, treatment with rhEpo induces the
production of mature RBCs, alleviating anemia in a significant proportion of
patients. Interestingly, due to the increase in RBC production and tissue oxygen
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delivery, Epo has been exploited as a doping agent in endurance related sports,
and has been banned in most countries by sporting governing agencies.79

Erythropoietin receptor. All biological effects of Epo occur after binding
of the cytokine to the cognate dimerized receptor, EpoR. The primary cell
lineage expressing EpoR is erythroid progenitors, although its expression has
been identified on a number of cell types including endothelial cells, mammary,
brain, kidney and cardiac muscle cells, and may be found on a number of nonhematologic tumor types.80-82 The EpoR is a Type I cytokine receptor with no
intrinsic kinase activity. Although it is responsible for all Epo induced cell
stimulation, there are predicted to be less than 1000 receptors per cell.70,79,83,84
This finding suggests that the regulation of its production, and cell surface
expression, is a highly regulated process.

EpoR maturation, transport, and turnover. Since the cloning of Epo
and subsequently its receptor, the maturation, transport, and turnover of the
receptor has been extensively investigated. Cell surface expression of the EpoR
is dependent on the Janus Kinase 2 (Jak2) protein.70 EpoR is initially contained
in the endoplasmic reticulum (ER) where only about 20% will mature and be
transported to the Golgi apparatus.83 Of the Golgi EpoR, only a small proportion
will fully mature and be transported to and expressed on the cell surface.83 This
demonstrates the highly regulated process of cellular EpoR expression and
assures that an excess of receptor is readily available under conditions of
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hypoxia and/or bleeding for the production of mature RBCs. Jak2 binds to the
EpoR in the ER and with assistance of an EndoH oligosaccharide, is transported
to the Golgi apparatus as a receptor complex.83 Full maturation of the receptor
and transport to the cell surface occurs after heavy glycosylation.83 Upon
receptor stimulation by its ligand, EpoR is ubiquitinated at the cell surface and is
quickly internalized into the cytoplasm. EpoR ubiquitination targets the protein
for proteasomal degradation which prevents further signal transduction by
removing the phosphorylated tyrosine residues on the cytoplasmic tail, and
allows parts of the receptor to be recycled.84-86 Two E3 ubiquitin ligases have
been implicated in the degradation of EpoR and Type I Jak2-associated cytokine
receptors, β-Trcp and RNF41.85,87 E3 ubiquitin ligases and their functions as
they relate to these investigations will be discussed in the E3 Ubiquitin Ligase
section.

EpoR signaling. Structure of the EpoR is similar to other Type I cytokine
receptors including a cytoplasmic, transmembrane, and extracellular domain and
no intrinsic kinase activity.78,88,89 The signaling cascade triggered by EpoR
stimulation has been extensively studied, and a generalized schematic is
summarized in Figure 4. Upon Epo binding to its receptor, a conformational
change of the receptor causes homodimerization.79,88 Dimerization causes the
phosphorylation and activation of the constitutively associated Jak2
protein.70,78,79,88,90 Mouse embryos without Jak2 lack RBCs.78 Jak2
autophosphorylates itself but also phosphorylates 8 tyrosine residues on the
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Figure 5. Schematic of EpoR Signaling. Erythropoietin binds EpoR which
homodimerizes and triggers auto-phosphorylation of Jak2. Jak2 phosphorylates
tyrosine residues on the cytoplasmic tail of EpoR as well as STAT5, the latter of
which then dimerizes and translocates into the nucleus where it binds DNA and
turns on pro-survival, proliferation, and differentiation genes.
The
transmembrane tyrosine phosphatase CD45 is a negative regulator of the
pathway, which dephosphorylates tyrosine residues on Jak2, lyn kinase, and the
EpoR cytoplasmic tail.
cytoplasmic tail of EpoR.78,79,89-91 These phosphorylated residues act as docking
sites for a number of other signaling intermediates via their SH2 homology
domains.70,78
Although a number of signaling pathways are activated by Epo stimulation,
perhaps the most extensively studied pathway involves the Signal Transducer

33

and Activator of Transcription (STAT)5.70,78,88,92 Jak2 phosphorylates STAT5
which initiates dimerization of the protein and translocation to the nucleus where
it binds DNA and initiates the transcription of anti-apoptotic genes such as Bcl-X,
a Bcl-2 family member protein.78,79,88,89,92 STAT5 deficient mouse embryos are
severely anemic.78 In addition to STAT5, activation of GATA-1 transcription
factor is necessary for erythroid cell development based on studies of null mouse
models.49,93 GATA-1 regulates a number of genes involved in erythroid
differentiation including EpoR and Sp1 genes as well as inhibiting apoptosis in
erythroid precursors.49,93 GATA-1 was shown to be activated through the
phosphotidyl-3 kinase (PI3K) /Akt pathway.94 Phosphorylation of GATA-1 by
PI3K is necessary for Epo induced growth of erythroid progenitors.94 The PI3K
pathway is activated in part through receptor binding of Grb2 and Vav. 70,78,79,89
Vav and Grb2 additionally activate Ras and Rac, members of the Rho GTPase
family of proteins78,89,95-97 The GTPases are molecular switches that cycle
between active GTP-bound and inactive GDP-bound states and are involved in
the regulation of cellular component trafficking and cytoskeletal changes.96,97
GTPases will be discussed in more detail later. Lyn kinase is also activated and
associated with the receptor at the cell surface.70,89 Lyn kinase phosphorylates
both the EpoR and Stat5 to cooperate in the potentiation of Epo signaling.89 The
mitogen-activated protein kinase (MAPK) pathway is similarly activated after Epo
stimulation, and has been shown to be additionally responsible for the activation
of Rho kinase.70,79,96 Regardless of the pathway involved, EpoR signaling
induced by cytokine stimulation is essential for not only basal RBC maintenance
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and production, but also in anemia caused by erythropoietic insult or hypoxia.
Therefore aberrations of this pathway are critical limiting factors in the
pathogenesis of anemia in select hematologic disease pathogeneses, and
provide possible therapeutic targets.

Negative regulation of EpoR signaling. Negative regulation of the
EpoR pathway is primarily coordinated through negative feedback loops.92 This
regulation is accomplished by a number of phosphatases and a family of proteins
known as the suppressors of cytokine signaling (SOCS). The SOCS proteins
bind Jak2 inactivating it, block STAT5 binding sites on the receptor, and
ubiquitinates signaling proteins, all of which halt Epo induced signaling.92 The
major phosphatases involved in the negative regulation of this pathway include
hematopoietic cell phosphatase (HCP, SHP-1 or PTP1C) and CD45.70,78,88,92
SHP-1 dephosphorylates Jak2 causing its inactivation and halting downstream
signaling.70,78,88 The transmembrane phosphatase, CD45, is essential for both Tcell and B-cell regulation, as well as EpoR signaling.98 CD45 dephosphorylates a
number of proteins including Jak2.98 Lastly, receptor recycling and turnover also
regulates Epo induced signaling. After ligand binds the receptor, it is
immediately ubiquitinated and either degraded or recycled back into the cell.86

EpoR signaling in MDS. Patients with MDS have comparable levels of
both endogenous Epo and normal cellular membrane density of EpoR, however,
clear functional inadequacies are evident compared to normal controls.49 Given
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that there is no identified loss of ligand binding to the receptor, impaired
activation of STAT5 must relate to a deficiency in the signaling pathway.49
Unfortunately, the exact mechanism underlying signal impairment remains
elusive. Hoesfloot et al. reported that there is a marked decrease in Epo induced
DNA transcription and binding of GATA-1 in MDS patients compared to normal
controls.49 A loss of GATA-1 transcriptional activity was followed by decreased
maturation in response to Epo, and loss of erythroid or Epo responsive cells.49 It
was also found that STAT5 activation after Epo stimulation was either
undetectable or at very low levels in MDS progenitors.49 The diminished STAT5
activation coincides with a decrease in erythroid colony-forming capacity and Epo
induced DNA synthesis.49 Furthermore, the decrease in STAT5 activation was
not due to low numbers of erythroid cells, suggesting that the site of dysfunction
is an early event likely preceding activation of STAT5.49 Furthermore, it suggests
that ineffective erythropoiesis in MDS may be caused by a defect in the signaling
cascade. Since Hoesfloot et al. published their reports in 1997, the mechanism
of decreased signaling has still yet to be identified. In this manuscript, we
propose that impairment in lipid raft signaling platforms are responsible for
decreased STAT5 activation and provide a novel finding on the disease biology
of MDS and possible therapeutic strategies.

Lipid Rafts

Identification and composition. The plasma membrane is a fluid
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phospholipid bilayer. Within this fluid membrane structure, discrete entities
composed of tightly packed sphingolipids and cholesterol ‘float’ freely. These
platforms are termed lipid, or membrane, rafts.99,100 The rigidity and relatively
ordered state of lipid rafts are a consequence of the saturated acyl chains on the
sphingolipids in contrast to the unsaturated fatty acyl chains of the
phospholipids.101 High levels of sphingolipids and cholesterol in the apical
domain of polarized epithelial cells was the first evidence of the existence of lipid
rafts.100,102-104 Since these initial findings almost 20 years ago, accumulating
evidence reveals that rafts are formed through a lateral association of
sphingolipids that are held together by their hydrocarbon chains and tightly
associated cholesterol molecules.102,105 Rafts are associated with
glycosylphosphatidylinositol (GPI)-anchored proteins, cytokine receptors, kinases,
and GTPases that mediate intracellular signaling in response to varied external
stimuli (Figure 6).102,105 The sterol composition of the lipid rafts renders them
relatively insoluble to detergent lysis at 4°C and therefore they are also
sometimes referred to as detergent resistant membranes (DRM) or detergentinsoluable, glycolipid-enriched complexes (DIGs).102,106 There is reported to be
10x more cholesterol in the raft fractions compared to non-raft fractions, however,
how much of the plasma membrane is actually accounted for by lipid rafts
remains controversial.106 Studies of raft size vary greatly but reports suggest that
they may range anywhere from 10-200nm.101,102 Although exact sizes of rafts
are disputed, it is agreed that they are relatively small under steady state
conditions, but that they increase in size due to aggregation upon external stimuli,
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Figure 6. Lipid Rafts. Lipid rafts are composed of tightly packed sphingolipids
and cholesterol forming platforms that contain GPI anchored proteins, cytokine
receptors, kinases, and GTPases that mediate cell signaling
a process which is necessary to mediate downstream signaling pathways.102,105

Raft formation. The process of raft assembly and aggregation is
accomplished through intricate coordination with the actin cytoskeleton.101 The
actin cytoskeleton is a dynamic assembly of subunits that changes in response to
external stimulation.107 Interaction between the actin cytoskeleton and lipid rafts
is suspected to be involved in protein trafficking as well as translocation of raft
subunits from the Golgi to the plasma membrane.101 Cholesterol is produced in
the ER, however, sphingolipids are produced in the Golgi.102 Raft assembly is
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initiated in the ER, but after component glycosylation, moves to the Golgi where
manufacturing occurs before translocation to the membrane.102,107,108
Sphingoliphid and cholesterol stores are maintained at the trans Golgi network
and are available under appropriate conditions to promote rapid coalescence and
recruitment of signaling molecules.107 Each of these processes is mediated
through the actin cytoskeleton.102,107,108 Although actin itself does not interact
with the lipid rafts, these proteins act as a scaffolding between the raft
constituents and cytoplasmic proteins, and also serves as tracks to guide protein
transport.101 The aggregation of rafts is dependent upon reorganization of
filamentous (F)-actin.101,107 These rearrangements are coordinated in part
through the dedicator of cytokinesis 2 (DOCK2) and Rac GTPases.101 RhoA and
Rho associated-coil-coil-containing protein kinase (ROCK) are also particularly
important for this process.101 Rac GTPases will be discussed in greater detail
shortly. The actin cytoskeleton is not only dynamic, but bidirectional, therefore
the same pathways leading to the formation of the rafts and shuttling to the
membrane, are also used in raft recycling and negative feedback loops.107
Endocytosis of rafts may lead to recycling back to the plasma membrane,
recycling back to the Golgi, or dissociation.109

Functions. Since their identification in polarized epithelial cells, lipid rafts
have since been implicated in a number of cellular processes. For example, rafts
are the point of entry for a number of infectious pathogens. Some pathogens
known to be dependent on rafts for cell invasion include the malaria parasite,
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Plasmodium falciparum, the influenza virus, and HIV-1.102,105,110-112 Disruption of
lipid rafts inhibited entry of each of these pathogens indicating a critical role of
the rafts in cell penetration and infection.102,105,110-112 Other raft functions can be
exemplified by showing the diversity of proteins that are functionally dependent
on membrane rafts. Both the B-cell receptor (BCR) with CD20 and CD19/CD21
complexes, and the T-cell receptor (TCR) are present in raft fractions.101,113 The
dependence of T-cell activation on lipid rafts has been extensively studied and
will be discussed in the next section. There are also a number of cytokine
receptors known to reside in rafts, including the vascular endothelial growth
factor (VEGF), granulocyte-macrophage colony stimulating factor (GM-CSF),
epidermal growth factor (EGFR), and insulin-like growth factor receptor
(IGFR).114 The presence of these cytokine receptors (and others) in lipid rafts
signifies the importance of rafts in cytokine signaling. The FcǫRI receptor,
important for IgE signaling resides in lipid rafts suggesting a role in allergic
reactions as well as parasite immunity.113 The death receptor complex,
Fas/CD95, also resides in lipid rafts implicating a role of in apoptosis.115 The
ATP-binding cassette transporters (ATP transporters) including P-glycoprotein
(Pgp) and Multidrug resistance-associated protein 1 (MRP-1) are located in rafts,
suggesting a role in multidrug resistance.116 G-protein coupled receptors
(GPCRs), such as the dopamine receptors, are constitutively associated with
lipid rafts implicating an importance for neuronal signaling.116-119 Ferroportin, the
protein responsible for iron export in macrophages, is dependent on lipid rafts.120
Integrins involved in cell to cell contact, migration, and metastasis also reside in
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the rafts.101 Rafts are also important for endocytosis, a process by which
receptors are internalized into the cell after ligation.102 Some of the most highly
raft associated proteins are the Src family kinases, such as Lyn kinase.102,105,113
Lyn kinase acts as a mediator between raft domains and signaling effectors
further supporting the important role of rafts in cell signaling. The presence and
functional dependence of these proteins on rafts localization demonstrates the
diversity and magnitude of cellular processes associated with these membrane
microdomains.

T-cell signaling. The role of lipid rafts in signaling has been most
extensively studied in T-cell activation.121 Upon stimulation, T-cell receptors
(TCR) coalesce in the lipid rafts, compartmentalizing with associated signaling
proteins.109,122 TCR is associated with GPI-anchored proteins and the clustering
of lipid rafts marks localization of the immune synapse.123,124 This clustering
occurs via the raft constituent, ezrin, an ERM (ezrin, radixin, moesin) protein that
links the plasma membrane and the actin scaffolding by crosslinking the actin
filaments.125 After TCR clustering, Zap-70 is recruited to the raft to act as a
bridge between the TCR and downstream signaling molecules.126 Coincidentally,
Zap70 recruitment to rafts is also necessary for the activation and recruitment of
protein kinase C-βII (PKC-βII) in BCR signaling.126 Several other T-cell
intermediates are then recruited to the raft fractions after TCR activation
including CD3ζ chain, SLP76, PKCθ, PLCγ1.101 Both PI3K and CARMA1
(caspase recruitment domain membrane-associated guanylate kinase 1) are also
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recruited to rafts in both T- and B-cells.101 Furthermore, the signal attenuating
tyrosine phosphatase, and transmembrane protein, CD45, is sequestered out of
the raft membrane upon TCR activation.121 Raft disruption blocked the
aggregation of TCR and the recruitment of these intermediates ultimately
inhibiting T-cell activation. The coordination of positive effecter recruitment and
negative regulator dismissal through raft organization is necessary to optimize Tcell signaling.

Immune synapse. The immune synapse is the site of cell to cell contact
for both T- and NK cells, and has abundant raft aggregation, allowing optimal
spatial organization of receptors and signaling intermediates. Raft aggregation
promotes the reorganization of the cytoskeleton that is necessary for the
formation of the immunological synapse.127,128 Raft aggregation and intermediate
recruitment at the synapse is ultimately responsible for the ability of both the Tand NK cells to perform their immunological functions. Actin filament assembly
and immune synapse formation in activated T-cells is dependent on the Arp2/3
complex, Wiscott-Aldrisch syndrome protein (WASp), the GTPase effecter,
mammalian homolog of diaphanous formin, mDia1, and the Rho/ROCK/LIMK
pathway .127,129 Disruption of these pathways result in impaired lipid raft
formation and limited the ability to form immunological synapses.127 After
receptor engagement at the immune synapse, rafts are endocytosed, following
integrin mediated detachment from the substratum, which is also dependent on
actin polymerization regulated in part by another GTPase Arf6.130 These
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GTPase activated cytoskeletal rearrangements will be discussed further under
the GTPases section of this manuscript. Raft disruption significantly and
negatively impacts immune synapse fidelity and decreases TCR activity,
illustrating the importance of rafts in immune response. It is now well accepted
that lipid rafts serve as signaling platforms that sequester receptors and
downstream signaling effectors sequester to facilitate signal transduction for a
number of receptor pathways, and in diverse cell types.102

Raft mediation of signaling cascades. Currently there are a number of
receptor pathways known to be initiated or mediated by rafts, however, the
question arises, how does this occur? Currently, there are several suggested
theories to explain how rafts coordinate receptor signaling, or vice versa, how
signaling cascades initiate raft aggregation. First, the affinity of cholesterol and
signaling intermediates may increase after raft coalescence.113 Alternatively,
rafts may be induced to coalescence upon protein aggregation at the plasma
membrane.113 Others suggest that raft activated enzymes may produce water
soluble phosphor-oligosaccharides that may activate downstream molecules, or,
that activation and/or aggregation of rafts induces the clustering of GPI-anchored
proteins, and that these proteins then in turn activate downstream signaling
molecules.102,105 Regardless of how it is accomplished, it is clear that raft
activation is important for signal initiation, and that rafts themselves are activated
and aggregated upon receptor-ligand engagement.
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Raft Experimentation. There have been a number of tools used to
visualize lipid rafts including electron microscopy, fluorescent resonance energy
transfer (FRET), single particle tracking, immunofluorescence, photonic force
microscopy, chemical crosslinking, and ultra-centrifugation in sucrose density
gradients.109,114 The composition of sterols in the lipid raft domains make them
relatively detergent-insoluble, particularly to Triton-X, at 4°C which allows for their
isolation and identification.102,106,113 Upon ultracentrifugation in sucrose density
gradients, the insoluble raft fractions will float to lower density matrices allowing
for study of both the rafts and their associated proteins.102,106,113 Another useful
tool in the study of lipid rafts takes advantage of the constituent raft ganglioside,
GM-1.105 The endotoxin, cholera toxin, from Vibrio cholera, is comprised of
subunits A and B (CT-B), and CT-B has high affinity for GM-1.105,113,131,132 This
selective interaction facilitates identification of lipid rafts in a number of assays.
CT-B may be conjugated to florochromes for GM-1 detection via
immunofluorescence and flow cytometry, or to horseradish peroxidase for
western blot detection. Many of these methods will be described in further detail
in Chapters 2 and 3 of this manuscript. Another important feature of lipid rafts is
the ability to disrupt them with the use of cyclic oligosaccharadides, i.e.
cyclodextrins.109,133 Cyclodextrins bind to and extract cholesterol from the
membrane effectively disrupting raft integrity with accompanying loss of all
associated proteins. Lipid raft integrity is highly dependent on cholesterol and
therefore its removal is of bitter consequence to raft fractions.106,133 Betacyclodextrins are the most highly attracted to cholesterol and therefore are most
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effective at removing the cholesterol from the plasma membrane.133 Furthermore,
the solubility of β-cyclodextrins increases by adding methyl groups, and methyl-β
cyclodextrin (MβCD) is the most commonly used agent for raft disruption.106,133
Cholesterol intercalating agents, such as nystatin, are alternative although less
effective disrupting agents.109,113 Instead of removing cholesterol from the
membrane as is the case with MβCD, nystatin binds to cholesterol in the
membrane, sequestering it and causing disruption of raft dependent signaling
cascades.106,134 Nystatin is an anti-fungal with structure similarity to
amphotericin B, as opposed to an HMG-CoA reductase inhibitor statins that block
cholesterol synthesis.135
As mentioned above, GTPases are associated with the raft fractions and
are important to drive reorganization of the cytoskeleton and as such warrant
further discussion.

GTPases

Ras superfamily. The Ras superfamily of GTPases is comprised of 154
members, grouped into 5 major branches based on sequence similarity, and are
involved in a number of cellular processes including signal transduction, cell
cycle regulation, and cytoskeletal reorganization (Figure 7).136 Furthermore, Ras
GTPases are associated with the lipids in the plasma membrane via
isoprenylation which is necessary for membrane attachment.137
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Ran (1)
Rho (20)

Ras GTPase
Superfamily
(154 members)
5 branches
(+9 additional
members)

Arf (27)

-Nuclear-cytoplasmic transport
-Mitotic spindle organization
-Signal Transduction
-Regulation of actin organization
-Cell shape, polarity, and movement
-Cell matrix interactions
-Vesicle trafficking
-Endocytosis
-Cell secretion
-Microtubule dynamics

Ras (36)

-Signal transduction
-Gene expression regulation
-Cell survival, proliferation, and differentiation

Rab (61)

-Vessicle trafficking
-Endocytosis
-Cell secretion

Figure 7. Ras superfamily. The Ras GTPase superfamily is comprised of 154
members that can be grouped into 5 major branches based on sequence
similarity with 9 additional members. Some of the cell process regulated by each
family is provided.

The Ras GTPases are small proteins which shuttle between inactive GDPbound states, and active GTP-bound states.136 The transition between GDPbound and GTP-bound is accomplished through guanine nucleotide exchange
factors (GEFs).136 Hydrolysis of GTP back to GDP is accomplished through
GTPase-activating proteins (GAPs).136 Rho and Rab GTPases are additionally
regulated through guanine nucleotide dissociation inhibitors (GDI) which can
block binding of GEFs and GAPs, and prevent the association of the GTPases to
the plasma membrane (Figure 8).136,138 Gene mutations of proteins that cause
an upregulation of Ras can be found in about 33% of all human cancers,
however, mutations of Ras itself are often not observed.136 Most commonly
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Figure 8. GTPase regulation. GTPases switch from inactive GDP bound states
and active GTP bound states via guanine exchange factors (GEFs) and GTPase
activating proteins (GAPs). Rho and Rab GTPases are also regulated by
guanine dissociation inhibitors (GDI) which prevent GEF and GAP binding to the
GTPases, and can block association with the plasma membrane.
these activating mutations are found in GEFs and GAPs.136 One of the most
important functions of the Ras GTPases is reorganization of the actin
cytoskeleton.

Cytoskeleton. The actin cytoskeleton performs a number of vital cell
functions including spatially organizing cellular components, serving as the
messenger between the intra-and extra-cellular environments, regulating cell
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movement and shape, and regulating cargo transport throughout the cell.139 The
cytoskeleton continually accommodates cellular changes based on stimuli
through reorganization of actin monomers.139 Actin polymerizes to form filaments
which can be bundled or branch out to form dynamic networks.139 The
cytoskeleton has three major components; microtubules, actin filaments, and
intermediate filaments.139 Microtubules are the stiffest and most complex
components and are best described in their role in cell division.139 Microtubules
are unique in the regard that they are either in a state of polymerization or
depolymerization, but never both simultaneously.139 Interestingly, microtubule
formation is activated by the GTPase Rac1 which in turn activates the
polymerization of microtubules creating a positive feedback loop.139 Actin
filaments are also highly organized, however, are less rigid than microtubules.139
Actin filaments form a scaffold that is held together by spectrin, forming a
hexagonal lattice that lies beneath the plasma membrane and allows tethering of
membrane associated proteins including GTPases.140 Actin filaments are
important for cytoskeletal reorganization based on external stimuli and are key to
lipid raft aggregation in response to these stimuli.141 Furthermore, actin filaments
are involved in the trafficking to and from the plasma membrane, as well as in the
internalization of ligand bound cytokine receptors. These processes are all
regulated by Rho GTPases.142 Both epidermal growth factor (EGF) and plateletderived growth factor receptor-β (PDGFR-β) are known to be endocytosed
through actin reorganization and are dependent on the activity of GTPases.140
Unlike microtubules, actin filaments are undergoing simultaneous polymerization
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and depolymerization, allowing constant rearrangement based on environmental
stimuli.139 Actin filaments continue to polymerize so long as there are available
monomers suggesting regulation by associated factors such as GTPases.139
Intermediate filaments are the least rigid components of the cytoskeleton,
however, they are the most efficient at resisting tensile forces making them
particularly important for actively circulating cells.139 One of the most well studied
branches of the Ras family are the Rho GTPases, which in addition to a number
of other cellular functions, are heavily involved in regulating these actin
cytoskeleton formations.136

Rho GTPases. Two of the most highly studied actin cytoskeletal
structures are stress fibers and membrane ruffles.143 In 1992, Ridley, Hall, and
colleagues found that the formation of these cytoskeletal elements was induced
by the activation of the Rho GTPases.143-145 This observation was the first
suggesting GTPases are involved in regulating cytoskeletal reorganization. The
Rho GTPases are comprised of 20 members that can be separated into 8
families based on sequence similarities (Figure 9).140 The three branches of the
Rho family known to be involved in action skeleton organization include the Rholike family (RhoA, RhoB, and RhoC), Rac-like family (Rac1, Rac2, and Rac3),
and Cdc42-like, whereas the best studied are RhoA, Rac1, and Cdc42.140,146
Although there is a high degree of sequence similarity between these proteins,
they have both overlapping and distinct functions. Additionally, there is
substantial crosstalk between them.143 Cytokine signaling induces membrane
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Figure 9. Rho GTPase family. The Rho GTPase family is comprised of 20
members that can be grouped into 8 subcategories based on sequence similarity.
The Rac-like, Cdc42-like, and Rho-like families are involved in signal
transduction and actin cytoskeleton reorganization.

ruffle formation at the leading edge of migrating cells and is controlled by Rho
GTPases.143 Activation of the actin cytoskeleton by Rho family members is
critical to a number of cellular processes including cell polarity, cell motility,
endocytosis, cell cycle regulation, vesicle trafficking, stress fiber formation, and
focal adhesions.143,147,148 Cytoskeletal reorganization via active Rho GTPases
has been implicated in cell metastasis and therefore may have a role in disease
progression.149 Receptor tyrosine kinase (RTK) phosphorylation prefers
proximity to lipid rafts, and reorganization of the cytoskeleton induces raft
aggregation and the recruitment of these receptors, processes that are
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dependent on the GTPases.127 Upon cytokine stimulation, Rho activates lipid raft
aggregation through the Rho kinases, ROCKI and ROCKII (ROCK).127 ROCK
phosphorylates LIM kinase (LIMK) which then inactivates cofilin through
inhibitory phosphorylation.127,150 When cofilin is phosphorylated it is no longer
able to bind to actin, and thereby, is unable to depolymerize actin filaments, thus
inducing actin polymerization.150 Rho subfamily GTPases also stimulate actin
polymerization and stress fiber formation via direct phosphorylation and
activation of the myosin light chain (MLC) and through ROCK which additionally
functions to inhibit MLC phosphatase.127,143,147,151 ROCK is also important for the
migration of macrophages and neutrophils which is accomplished through
regulation of PTEN.152 Additionally, Rho acts through another GTPase effecter,
mDia.142,143,147 mDIA is part of the formin family of proteins that are known
regulators of the actin cytoskeletal.153 Active mDIA promotes actin
polymerization by promoting binding of monomers to branched ends of filaments
and is important for the interactions of endosomes and the cytoskeleton.142,143,154
Interestingly, the gene encoding mDia1, DIAPH1, is located within the commonly
deleted region of del(5q) and mice lacking DIAPH1 develop a myelodysplastic
phenotype implicating a role in disease pathogenesis.155,156 In del(5q) MDS, it is
thought that loss of DIAPH1 inhibits the sensing ability of the actin cytoskeleton
and somehow promotes the expansion of the del(5q) clones although it is not
clear how this is done.154 Lastly, Rho actives actin polymerization through WASp
and Arp2/3 proteins.157 When activated, Rho proteins activate downstream
signaling effectors and actin skeleton reorganization.140,147
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Rac GTPases. The Rac family GTPases are involved in lamellipodia, membrane
ruffle formation, axon growth, cell adhesion, phagocytosis, and cell
differentiation.140,143 Rac proteins very actively induce actin polymerization
through the WASp family protein, WAVE/Scar (Figure 10).143 WAVE/Scar
activates the Arp2/3 proteins which are responsible for the binding of actin
monomers to filaments, causing the branching and weblike matrix of the actin
cytoskeleton.143 Rac activates WAVE through 2 mechanisms; 1) the activation of
IRSp53, and 2) the forced dissociation of Nap125, PIR121, and/orHSPC3000
from WAVE/Scar allowing the latter to activate the Arp2/3 proteins.140,143 Rac
also inhibits the actin depolymerizing protein, cofilin, further inducing actin
polymerization.140 Rac proteins are responsible for lamellipodium and membrane
ruffling and extension.140 These likely occur through activation of the DOCK
proteins.140 Although the Rac proteins have very similar sequences, they seem
to have distinct roles depending on cell type.140 Rac1 is observed in most cell
types whereas Rac2 is predominantly expressed in hematopoietic lineages, and
Rac3 is found mainly in the brain suggesting specific roles of Rac members in
tissue specific contexts.140

Cdc42. Cdc42 induces filopodia formation and is involved in cell polarization and
protrusion. Additionally, Cdc42 (and Rac1) are involved in cell cycle regulation
particularly at the G1/S checkpoint, through a MAPK dependent pathway.146,147
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Figure 10. Rho GTPase activation of cytoskeletal reorganization. The Rho
GTPases regulate actin cytoskeletal reorganization through a number of different
pathways shown here.

The filopodia formed by Cdc42 are composed of bundles of F-actin and serve as
“scouts” sensing the cell surroundings and relaying messages to the inside of the
cell.140 The downstream targets of Cdc42 are WASp (that activates the Arp2/3
proteins), and mDIA, which induces formation of unbranched actin filaments.
In summary the Rho GTPases induce actin polymerization and cytoskeletal
reorganization though a number of mechanisms including activation of actin
nucleating Arp2/3 proteins, increasing myosin phosphorylation, through ROCK
which inhibits MLC phosphatase to augment LIMK phosphorylation, and through
the formin proteins such as mDIA (Figure 10).140,152,158
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GTPases and hematopoiesis. The Rho GTPases have key functions in
hematopoiesis. Some of the first evidence for this derives from investigations
showing that HSCs deficient for Rac1 and Rac2 have decreased myelo-and
erythropoiesis.159 Subsequent studies showed that Rho GTPases regulate HSC
survival, proliferation, and engraftment in transplantation models.128,146 The Rho
GTPases also regulate HSC interaction with the bone marrow niche.160 Early
erythropoiesis in the bone marrow is dependent on Rac1 and Rac2, which are
responsible for cytoskeletal arrangements in erythrocytes.159,161 The GTPases
function in erythrocytes via activation of mDia2.159 Furthermore, mDia2 was
found to be necessary for the maintenance of myeloid homeostasis, while RhoB
deficiency induces myelodysplasia in mice.155,156 Rac was also found to be
important for the creation of the actin scaffolding at the plasma membrane in
erythrocytes.140 Furthermore, Rac GTPases are necessary for erythrocyte
enucleation via mDia2.160 In their review, Mulloy et al. note that GTPases are
involved in nearly every step of hematopoiesis and differentiation of all
lineages.160

Rho GTPases and IMiDs. Rho GTPases are activated by IMiDs resulting
in cytoskeletal reorganization.128 IMiD activated RhoA and Rac1 induced
cytoskeletal reorganization in lymphocytes within minutes, whereas Cdc42 did
not have similar effects even after extended periods of exposure.128
Pomalidomide and LEN induced F-actin polymerization was dependent on RhoA
and Rac1 activity.128 Pomalidomide increased microtubule stabilization and actin
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polymerization at the apex of migrating cells through ROCK1.128 These effects
were specific to cell lineages as they were not found in all cell lines tested.128
However, these reports were the first to indicate that activation of GTPases is a
biological effect of IMiD treatment. Although it is now known that the IMiDs
activate the GTPases, it is not clear how this activation is mediated. We
hypothesize here, that actin reorganization via activation of the GTPases after
IMiD treatment may occur through inhibition of GTPase E3 ubiquitination.

E3 Ubiquitin ligases

Overview. Ubiquitination is a process by which ubiquitin (Ub), a 76 amino
acid peptide, is transferred to a lysine residue on a target protein marking that
protein for a number of cellular processes including intracellular trafficking, gene
regulation, DNA repair, and proteasomal degradation.162-165 Ubiquitin has 7
lysine residues that may be used for a number of different ubiquitin chain
combinations.166 Ubiquitin can be added linearly or may branch out forming
complex structures, the functions of which are not completely understood (Figure
11).164 The complex nature, and vast possibilities of Ub chains, may be
considered as an “ubiquitin code,” which may relay specific signals to target
proteins directing a number of different outputs.164 Polyubiquitination (occurring
at lysine 48) of at least four subunits, in general, targets a protein for degradation,
whereas, mono-, di-, or tri-ubiquitination (on lysine 63) often signals other cellular
tasks.163,164 Polyubiquitination causes degradation by targeting the protein to the
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Figure 11. The ubiquitin code. The process of substrate ubiquitination targets a
substrate for a number of cellular processes including gene regulation, DNA
repair, and proteasomal degradation. Ubiquitin monomers may be added linearly,
or may form branched chains. The sequence and structure of these chains
marks the substrate for different functions although the exact code is not
completely understood..
26S proteasome.164,165,167 The 26S proteasome is comprised of 2 subunits, the
20S proteolytic core and the 19S regulatory unit capping the 20S at both ends.165
When a ubiquitinated protein is delivered to the proteasome it is de-ubiquitinated
then unfolded by ATPases at the 19S subunit.165 It is then delivered to the core
proteolytic subunit where degradation occurs.165 Ubiquitinating complexes are
composed of three subunits; the ubiquitin-activating enzyme, E1, which uses
ATP to transfer a ubiquitin molecule to the conjugating enzyme, E2, which acts
as the donor for the ubiquitin ligase enzyme, E3 that is responsible for the
transfer of the ubiquitin from the E2 to the substrate receptor.163,164,166,167
There are two main classes of E3 ligases, HECT (homologous to E6-AP Cterminus) and RING (really interesting new gene) domain ligases which are
presumed to have different target motifs.162-164 Currently, there are only about 30
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known HECT ligases but more than 600 suspected RING domain ligases.166
Interestingly, there are only two known E1s and less than 40 E2s suggesting the
E3s are responsible for specificity.163 The major difference between RING and
HECT E3 ligases, in addition to domain and structure differences, is how they
transfer the ubiquitin group from the E2 to the substrate receptor (Figure 12).166
RING ligases directly transfer the ubiquitin from the E2 to the acceptor acting as
a platform connecting the E2 and substrate. However, HECT ligases first
transfer the ubiquitin to an activated cysteine residue on the E3 ligase before
then transferring it to the substrate.166 Recently, pseudo RING/HECT hybrids
were identified, that are collectively referred to as RING-in-between-RING (RBR)
ligases and will not be discussed in this manuscript.164

Figure 12. E3 ligases. There are two major groups of E3 ubiquitin ligases. The
RING domain ligases act as a platform for the direct transfer of an ubiquitin
monomer from the E2 to the substrate acceptor. HECT ligases first transfer the
ubiquitin from the E2 to an activated cysteine on the HECT ligase, then transfers
it to the substrate.

E3 ligase regulation. Regulation of E3 ligases is often accomplished by
post-translational modification and/or substrate availability.163 Both the E2 and
E3 subunits may be phosphorylated which is one mechanism by which regulation
is achieved.163 E3s can also be regulated by specific binding partners, by
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ubiquitin like peptides, or by small molecules changing the affinity of the E3 for
either the E2 or target Ub acceptor.163 Additionally, there are about 100
deubiquitinating enzymes (DUB) that regulate E3 ligase activity by removing
ubiquitin groups.162,164 Of particular importance is the fact that E3 ligases
themselves may be ubiquitinated and targeted for degradation either by other E3
ligases, or in many cases, by auto-ubiquitination.163 Since E3 ligases effect so
many cellular processes, their regulation is of utmost importance. As such,
deregulation of E3 ligases have been linked to a number of human disorders
including Parkinson’s disease and many different malignancies.163,167

Plasma membrane development and protein turnover. The
translocation of plasma membrane machinery and associated proteins are
controlled by the secretory pathway (which brings components to the cell
surface) and the endocytic pathway (which is responsible for the internalization
or recycling of membrane components to the intracellular compartment) both of
which are controlled in part through ubiquitination complexes.162 Although
ubiquitination does not seem to play a role in the transport of proteins from the
ER to the Golgi, it is responsible for the degradation of misfolded ER proteins,
and plays a role in Golgi sorting. Any misfolded proteins that escape ER
degradation, may be marked for degradation by what is known as the Golgi
complex quality control (GQC) system.162 E3 ligases are also responsible for
protein transport to the plasma membrane through vesicles, although the exact
mechanisms are not completely understood.162 There are numerous reports
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suggesting dependence of endocytosis on ubiquitination, particularly of plasma
membrane components.162 Both RTKs and GPCRs are endocytosed after
ligation through endocytic pathways which are dependent on ubiquitination.162
Upon stimulation these receptors are ubiquitinated triggering their
internalization.162 The specific roles and specific ligases in endocytosis are not
fully understood in part due to the number of roles the endocytic pathway
plays.162 For example, receptor internalization may direct the receptor to be
either degraded by the proteasome or recycled back to the plasma membrane.162
In fact, proteins may be sent back to the plasma membrane, sent to the
proteasome, or sent to the Golgi for recycling.162 Also, not all endocytosed
proteins are ubiquitinated.162 It is believed that endocytic sorting may involve the
cooperation between E3 ligases and DUBs, a process that is complicated by the
fact that internalized plasma membrane proteins can interact with other
cytoplasmic proteins to promote the formation of new complexes with new
cellular roles for the recycled plasma membrane component, the E3 ligases
involved in its internalization, and cooperating effects of the DUBs.162 It is
believed that when the E3 ligase is associated with ESCRT (endosomal sorting
complex required for transport), the substrate protein will be bound to the
lysosome and ultimately for degradation. However, further studies are necessary
to confirm these findings.162
The role of E3 ligases is pivotal to a number of cellular processes
including regulating components of the plasma membrane and the turnover of
important signaling receptors. Although there are hundreds of ubiquitin ligase
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complexes, it is important for purposes of this manuscript to further discuss three
specific RING family members, cereblon, MDM2, and RNF41.

Cereblon. Cereblon (CRBN) is a 442 amino acid protein that is part of an
E3 ubiquitin ligase complex that includes Cullin 4, regulator of cullins-1 (Roc1),
and damaged DNA binding protein-1 (DDB1).39,168 Roc1 and DDB1 form the
catalytic core of the complex that interacts with E2 enzymes.43 DDB1 also
connects Cul4 with the substrate.43 The exact role of CRBN in the complex is
unknown. CRBN is highly expressed in the human brain and may have a role in
memory and learning.168 Truncations of CRBN are associated with mental
retardation.168 Although the importance of CRBN in brain development is not
new, studies in the last 3 years have shown an important role in IMiD activity.169
Ito et al. reported that the direct binding target of thalidomide responsible for its
teratogenic effects, is the CRBN-DDB1 complex.169 The Cul4-E3 ligases are
known to be important for embryonic development and after more than 40 years
of investigation, and over 30 different hypotheses, direct biding of thalidomide to
CRBN is now accepted as the mechanism by which thalidomide induces
teratogenicity. 39,43,168,169 However, there are likely other factors that contribute to
teratogenicity since malformations are observed in specific tissues (brain and
limbs) despite the fact that CRBN is expressed in all cell lineages.43 Interestingly,
thalidomide is not teratogenic in mice despite 95% sequence similarity between
human and mouse CRBN, and similar binding affinities of thalidomide and
CRBN.43 There are a number of hypotheses proposed to explain this including
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differential breakdown of hydrolyzed byproducts of thalidomide between mice
and humans, differences in the biological activity of thalidomide, and a lack of
ROS formation induced by thalidomide in mice due to a stronger anti-oxidant
response.43
Direct binding of thalidomide to CRBN causes inhibition of the ubiquitin
ligase function of the CRBN complex.43,169 In addition to the inhibition of ligase
activity on substrates, IMiDs also inhibit the auto-ubiquitination ability of CRBN
further regulating its function.39,168 Recent investigations have implicated CRBN
in the anti-neoplastic effects of thalidomide and LEN in MM.168,170,171 This finding
implies that the E3 ligase activity of CRBN is necessary for degradation of some
regulators important in the maintenance and/or survival of MM cells.168,170,171
These findings were not specific to thalidomide as both pomalidomide and LEN
were also found to bind to CRBN, and this interaction was equally as important in
the anti-proliferative effects in MM cells.170 Not surprisingly, pomalidomide or
LEN resistant myeloma cells have decreased levels of CRBN.170 The importance
of these findings is threefold; first, they are the first time a direct biding partner of
the IMiDs has been identified. Second, the importance of CRBN in mediating
varied biological effects of the IMiDs in MM may increase knowledge of MM
disease biology as well as other hematological malignancies responsive to IMiDs
such as MDS. And lastly, the finding that IMiDs can inhibit E3 ligase activity has
major implications in what is known about the overall biological effects of the
IMiDs.
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MDM2. The murine double minute-2 (MDM2) protein is the major
negative regulator of p53.172 P53 is well known to be involved in a number of
cellular processes including cell cycle regulation, apoptosis, DNA repair, and
senescence.173 MDM2 is capable of negatively regulating p53 by two
mechanisms.172,173 First, MDM2 binds p53 at the N-terminus of MDM2, thereby
preventing p53 binding to DNA and preventing transcriptional activity.172,173
Although, MDM2 blocks p53 binding to DNA, its primary regulation is through
ubiquitination and ultimately degradation by the proteasome.172,173 Since the
RING domain is in the C-terminus of MDM2, the two methods by which MDM2
regulates p53 can be ascertained after a stimulus is provided.172,173 Regulation
of p53 is of utmost importance as it is upregulated under cytotoxic stress (such
as genotoxic stress, hypoxia, heat shock or others.)173 However, high levels or
sustained activation of p53 promotes apoptosis, indicating the need for strict
regulation and negative feedback.172,173

Interestingly, p53 activates MDM2

transcription creating its own negative feedback loop.172 When p53 is activated
by stress it activates MDM2 transcription, MDM2 will then bind to p53 targeting it
for degradation thereby completing the loop.172,173 In addition to p53, MDM2
binds and ubiquitinates several other proteins with p53 sequence homology
including p73, p63, p51, and E2F1 blocking the transactivation of each.172,173
Although there are a number of E3 ligases that ubiquitinate p53 including the
HECT E3 ligase, E6AP, Cul4-DDB1 complex, CBP/p300 and others, MDM2 is
thought to be the primary regulator.173 MDM2 gene overexpression is observed
in up to 7% of all cancers, with up to 20% of all soft tissue tumors.172 Therefore,
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MDM2 is a potential therapeutic target for functional interference to stabilize p53
and induce apoptosis of malignant clones.172 Additionally, the MDM2 homolog,
MDMX, also ubiquitinates p53 in both an MDM2 dependent and independent
manner. MDM2 and MDMX can heterodimerize further regulating their activity in
p53 degradation.172-174 Both MDM2 and MDMX deficient mouse embryos are
non-viable.172,173 Interestingly, when p53 was knocked out in MDM2 or MDMX
embryos, viability of the embryos was restored indicating that the loss of MDM2
or MDMX caused cell death in a p53 dependent manner.172-174
Our laboratory and colleagues recently reported that LEN inhibits the autoubiquitination of MDM2, stabilizing the protein, and promoting the degradation of
p53.175 In del(5q) MDS, there is accumulation of p53 resulting from nucleolar
stress and the release of unbound ribosomal proteins in the nucleus. This results
from haplosufficiency of RPS14.23 The unbound ribosomal proteins bind to and
promote the degradation of MDM2 causing an accumulation of p53. Treatment
of del(5q) patients with LEN decreased p53 expression, caused by stabilization
of MDM2 by inhibiting its autoubiquitination function similar to that which occurs
with CRBN.175

RNF41. RNF41 [ring finger protein 41, neuregulin receptor degradation
protein-1 (Nrdp1), fetal liver ring finger (FLRF)] is an E3 ubiquitin ligase that has
several roles.87 First, it is responsible for the ubiquitination and degradation of
two additional E3 ligases, BRUCE and parkin.87,176 BRUCE is an inhibitor of
apoptosis and parkin is known to be associated with disease pathogenesis of
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Parkinson’s disease.87 RNF41 regulates Toll-like receptor (TLR) signaling via
ubiquitination of MyD88.87 RNF41 is also involved in the steady state levels of
cytokine receptors, ErbB3 and ErbB4.87,176,177 RNF41 interacts with these
receptors independent of ligand binding, ubiquitinates them, and targets them for
degradation and internalization.87,177 It was also found that RNF41 can regulate
the steady state membrane expression of other cytokine receptors including IL3
and EpoR.87 It has since been determined that RNF41 is responsible for Jak2associated Type I cytokine receptor ubiquitination and degradation.87
Furthermore, the regulation of cytokine receptors suggests that RNF41 may also
be involved in hematopoiesis. RNF41 overexpression inhibited HSC
differentiation consistent with decreased levels of EpoR and IL3.176 The role of
RNF41 in Jak2-associated, Type I cytokine regulation is particularly important for
this study due to its role in EpoR expression and necessity for steady state
erythropoiesis.

E3 ligases of GTPases. Ubiquitination and proteasomal degradation of
GTPases was not found until 2001.137 As RhoA, Rac1, and Cdc42 are the most
well studied GTPases, the ubiquitination of these proteins was studied first.
There are currently two known E3 ligases specific to RhoA and these include the
HECT ligase SMURF1 (SMAD ubiquitination regulatory factor 1) and CRL3
complex (Cullin-RING ubiquitin ligase).137,166 SMURF1 activation caused a
decrease in F-actin polymerization and cell motility suggesting loss of RhoA
activity.166 Furthermore, loss of Cullin-3 induced actin polymerization in HeLa
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cells again suggesting its activity of RhoA inhibition.166 Although Cdc42 is
ubiquitinated and proteasomally degraded, the exact E3 ligases responsible for
this are not yet known.137,166 The RING ligase Cullin-1 is known to ubiquitinate
and cause the degradation of two known GEFs of Cdc42, FGD1 and FGD3, and
therefore it is thought that proteasomal regulation of Cdc42 is accomplished
primarily through regulating the GEFs and/or GAPs that interact with it.166
Interestingly, Cdc42 is thought to regulate RhoA expression by binding
SMURF1.137 Rac1 is also proteasomally degraded after ubiquitination, but the
ligase responsible was unknown until just recently.137 The HECT E3 ligase,
HACE1, is responsible for the ubiquitination and degradation of Rac1 and was
discovered after RNAi-based screening.178,179 HACE1 deletion increased Rac1
expression, however, had no effect on RhoA or Cdc42. 178,179 Also of interest
was the fact the HACE1 had a two-fold higher affinity for GTP bound rather than
GDP bound Rac1 implicating that ubiquitination occurs after activation.178,179
The identification of specific E3 ligases of GTPases is still in its infancy
and further studies should elicit the roles of these ligases in signaling response
and F-actin reorganization. We suspect IMiD induced activation of F-actin
polymerization, lipid raft aggregation, and signal intermediate recruitment is
accomplished through activation of the GTPases and broad E3 ligase inhibition
capabilities of the IMiDs, the supporting data of which follows.
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CHAPTER 2
Erythropoietin Receptor Signaling is Membrane Raft Dependent

A note to the reader: This chapter has been previously published in the journal
PLoS One, McGraw et al. 2012. 7(4):e34477, and has been reproduced here with
permission from the publisher.

Introduction
Erythropoietin (Epo) is the principal regulator of red blood cell
production.89,90 Upon Epo binding to its cognate receptor (R), the EpoR
homodimerizes to initiate activation of the non-receptor tyrosine kinases JAK2
and Lyn, which in turn phosphorylates the receptor’s cytoplasmic tail and the
signal transducer and activator of transcription 5 (STAT5).89,90,180 Dimerization of
phospho (P)-STAT5 enables its translocation to the nucleus and binding to target
gene promoters, ultimately promoting the expansion, differentiation, and survival
of red blood cell precursors.89,90,180 The Epo signaling pathway is regulated by a
balance of phosphatase and kinase activities.180 Lyn kinase has been shown to
enhance proliferation of erythroid progenitors by increasing colony forming
capacity and promoting progenitor maturation.181,182 Loss of Lyn inhibits
activation of STAT5 presumably through activation of negative regulatory
phosphatases, such as Src homology domain-containing phosphatase-1 (SHP-1),
SHP-2, and Src homology-2 domain-containing inositol 5-phosphatase 1 (SHIP1).183,184 Furthermore, association of Lyn with, and phosphorylation of EpoR and
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STAT5, promotes activation of downstream signaling.185 Although the signaling
cascade initiated by Epo and the balance of phosphatase and kinase activity has
been well studied, the role of receptor localization in the plasma membrane and
its effect on signal integrity has not been investigated.
The plasma membrane of hematopoietic cells contains sphingolipid and
cholesterol enriched microdomains called lipid or membrane rafts.100,186 Lipid
rafts represent hydrophobic, detergent-insoluble membrane fractions enriched in
glycolipids and cholesterol. As a consequence, lipid rafts migrate to low density
matrices upon gradient centrifugation allowing the isolation of raft membrane
fractions and associated proteins.105,109 Lipid rafts are specialized membrane
microdomains that cluster signaling intermediates to create focused signaling
platforms that facilitate receptor-induced activation of signal transduction
molecules. Rafts rapidly coalesce to form aggregates in response to cytokine
stimulation or integrin engagement to optimize signal transduction.109,187-189 The
clustering of rafts serves to expose proteins to a membrane environment
enriched in components that amplify the signaling cascade, including kinases,
scaffold and adaptor proteins, substrates, as well as redistribution of regulatory
phosphatases.109,187-189 Recent investigations have shown that raft
microdomains have a critical role in T-cell receptor, c-kit and integrin signaling,
protein trafficking, endocytosis, as well as many other diverse cellular
functions.109,121,122,190-193 In this study, we examined the role of lipid raft
recruitment in EpoR signaling, receptor interaction with signaling intermediates,
and EpoR signal integrity.

67

Results

Epo induces raft formation and aggregation. Lipid raft microdomains
are characterized by their insoluble nature in non-ionic detergents as well as the
presence of the constituent ganglioside GM-1 and double acylated proteins such
as the Src-family kinase and Lyn kinase. We first investigated whether Epo
affects membrane raft assembly or raft coalescence by assessing changes in
membrane fraction distribution of GM-1 and Lyn kinase after Epo stimulation.
Dot blot analysis of fractionated UT7 cell lysates revealed a greater than 5-fold
increase of GM-1 in the detergent insoluble raft membrane fractions (fractions 1
and 2) after Epo exposure (Fig 13A), accompanied by increased raft partitioning
of Lyn kinase (Fig 13B). To verify that the detergent insoluble fractions
represented lipid rafts, we treated cells with a known membrane cholesterol
chelating agent, methyl-β-cyclodextrin (MBCD), to disrupt raft integrity, and
examined GM-1 and Lyn partitioning in membrane fractions. Treatment with
MBCD abrogated partitioning of either GM-1 or Lyn into the detergent-insoluble
membrane fractions, consistent with lipid raft distribution (Figs 13A and B).
In T-lymphocytes, clustering of lipid rafts is an essential step in the formation of
an immune synapse in response to antigen activation of the T-cell receptor 122.
To determine if Epo promotes raft coalescence, we quantitated changes in GM-1
labeled clusters after growth factor treatment. Raft accumulation in UT7 cells
after Epo stimulation increased (Fig 13C), accompanied by a significant increase

68

Figure 13. Epo stimulation induces raft formation and aggregation. (A) Dot blot
detection of GM-1 in UT7 cell lysates in non-raft (fractions 5, 6) and raft fractions
(fraction 2) with corresponding densitometry value in controls, and after Epo or
MBCD treatment. Representative blot of at least three independent experiments.
(B) Western immunoblot of Lyn in raft (R) (fractions 1-2) and non-raft (NR)
fractions (fractions 4-6). Treatment with Epo increased Lyn kinase incorporation
into raft fractions, whereas raft disruption by cholesterol depletion with MβCD
precluded Lyn incorporation. Representative western of at least three
independent experiments. (C) Immunofluorescence of UT7 cells showing an
increase in raft (red) accumulation after Epo exposure. (D) Immunofluorescence
of UT7 cells before and after Epo stimulation showing increased raft aggregates
(red) in the plasma membrane and corresponding quantitation.
(E)
Immunofluorescence of primary erythroid bursts showing an increase in cellular
membrane raft fluorescence intensity (red). Immunofluorescence experiments
were repeated at least 3 times, representative micrographs displayed.

in the mean number of raft aggregates (4.3 ± 1.4 per cell in untreated controls
compared to 25.6 ± 3.2 aggregates per cell after Epo stimulation) (Fig 13D; p ≤
0.001). The size of raft aggregates also increased after Epo treatment, with a
3.33 ± 0.11 fold increase compared to unstimulated controls (p ≤ 0.001). To
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verify that the observed changes in raft dynamics in UT7 cells extends to normal
erythroid progenitors, we assessed raft assembly in bone marrow erythroid
bursts derived from a normal donor. BFU-E were isolated by pipetting colonies
grown in methylcellulose assays after 14 days incubation. Immunofluorescence
staining for GM-1 (Fig 13E) showed that mean raft fluorescence intensity in
primary erythroid progenitors increased 58.4% from 72.79 ± 14/cell in
unstimulated cells to 115.27 ± 14.22 after Epo treatment (p=0.01).

EpoR co-localizes within lipid rafts. Recruitment of the T-cell receptor
into lipid rafts is a dynamic process, triggered by major histocompatability antigen
engagement .109 To determine if the EpoR co-localizes within raft microdomains
and is influenced by ligand engagement, we assessed EpoR localization by
confocal microscopy with and without Epo stimulation. EpoR rapidly co-localized
with GM-1 in UT7 cells after Epo stimulation (Fig 14A, rows 1 and 2).
Translocation of the EpoR to membrane rafts after Epo treatment was also
confirmed in primary bone marrow erythroid bursts (Fig 14A, rows 3 and 4).
In addition to immature erythroid progenitors such as burst forming units
(BFU-E), colocalization of EpoR in GM-1 raft clusters was also observed in more
mature, enucleated erythroid cells after Epo stimulation (Fig 14A, bottom row).
To further illustrate the recruitment of receptor to the rafts, we utilized the power
of 3D rendering. Figure 14B is a representative micrograph of an unstimulated
(left) and stimulated (right) UT7 cell in which the number of rafts is increased
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Figure 14. EpoR co-localizes with lipid rafts. (A) Confocal immunofluorescence
of cells untreated or after Epo stimulation, lipid rafts:red, EpoR:green,
DAPI/Hoechst:blue. Right panel is a merged image showing lipid raft and EpoR
co-localization (yellow). UT7 cells are shown in rows 1 and 2, while human
primary burst forming units are shown in rows 3 and 4, followed by a maturing,
enucleated erythroid precursor in row 5. (B) Three dimensional rendering of UT7
cells either untreated (left) or after Epo treatment (right). Top two rows display
isosurfacing of the rafts (red), EpoR (green), and nucleus (Dapi, blue). Dapi was
removed from the middle row to further visualize association of the receptor with
rafts in the second row of panels. The bottom row displays volume rendering of
the same cells to illustrate membrane colocalization (yellow). (C) Quantitation of
colocalization in human primary erythroid cells. Values represent mean ± SE.
Immunofluorescence experiments were repeated at least 3 times, representative
micrographs provided.

(red) as well as the recruitment of the receptor (green) to these domains. The
bottom row in Figure 14B utilizes volume rendering to emphasize the
colocalization (yellow) of the rafts and receptor on the cell surface. We used the
Pearson’s coefficient to quantitate the percent of colocalization in primary BFU-E
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cells where there is a significant increase in colocalization after Epo stimulation
(p = 0.02) (Fig 14C). EpoR membrane dynamics were further investigated by
western blot analysis of membrane fractions from UT7 cell lysates isolated by
gradient centrifugation. Raft (R) and non-raft (NR) fractions were pooled and
separated by SDS-PAGE. EpoR was not detected in lipid rafts from unstimulated
cells, but was restricted to the membrane and cytosol fractions. After 10 min of
Epo exposure, the receptor translocated into raft fractions (Fig 14A), confirming
that EpoR ligand engagement triggers redistribution of the receptor to membrane
raft microdomains. To confirm EpoR specificity of antibody immuno-reactivity,
receptor translocation was confirmed with several commercially available
antibodies, including the Abcam mouse mAb (MM-0031-6G7) (Cambridge, MA),
the Abcam goat polyclonal EpoR antibody, and the monoclonal A82 EpoR
antibody generously provided by Amgen (Thousand Oaks, CA), each of which
confirmed our findings of ligand induced raft translocation. 80,194-196 Densitometry
analysis of 2 independent experiments using all 4 of the above mentioned
antibodies is presented in Figure 15A. Based on recent investigations validating
the specificity of the Santa Cruz Biotechnology (Santa Cruz, CA) EpoR antibody
(M-20), this antibody was used preferentially in subsequent experiments.81
Furthermore, although Epo signaling is known to diminish after 10 minutes, we
next investigated an extended range of intervals after Epo stimulation to discern
the rapidity of receptor translocation into raft fractions (Fig 15B). EpoR was
recruited into the raft fractions within 1 minute of growth factor exposure,
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reaching a peak at 10 minutes, followed by gradual redistribution that was
completed by 60 minutes.

Epo engagement initiates recruitment of signaling intermediates into
lipid raft fractions. Because EpoR was recruited into membrane rafts after
growth factor stimulation, we investigated subcellular localization of
corresponding signal effectors to determine if receptor translocation was
coordinated with effector molecules to form discrete membrane platforms for
receptor signaling. Immunostaining of membrane fractions for STAT5, JAK2, Lyn,
and CD45 showed that Lyn and CD45 were constitutively localized in raft
fractions in unstimulated cells, whereas JAK2 was absent with minimal detection
of STAT5 (Fig 15C). After Epo stimulation, both JAK2 and STAT5 (principal Epo
signaling proteins) translocated into raft fractions accompanied by an increase in
Lyn kinase. However, CD45, a receptor tyrosine phosphatase and key negative
regulator of EpoR signaling, was excluded from raft fractions and re-partitioned
entirely into non-raft fractions (Fig 15C). The differential localization of CD45
after Epo stimulation suggests that growth factor activation initiates a controlled
process of raft assembly and aggregation favoring the recruitment of effector
molecules supporting receptor signal transduction. Furthermore, we were able to
show that the activated forms of both Jak2 and Stat5, as well as the alternative
Epo signaling pathway, MAPK proteins, accompanied EpoR in raft fractions after
growth factor stimulation (Fig 15D).
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Figure 15. Epo stimulation recruits signal effectors into raft fractions. (A) Raft
fractions (R) were separated from non-raft fractions (NR) and immunoblotted for
EpoR to investigate receptor translocation into rafts after Epo stimulation.
Corresponding quantitation represents the mean ± SE of two independent
experiments using four different EpoR antibodies. (B) Raft fractions were
isolated after stimulation with Epo at the indicated time points and immunoblotted
for EpoR. Results show that EpoR is recruited into rafts within 1 minute of Epo
stimulation reaching maximum loading at 10 minutes, followed by gradual
redistribution thereafter.
Accompanying graphic quantitation of the
representative experiment. (C) UT7 cells were starved overnight then treated
with Epo for 10 min. After fractionation, the non-raft (NR) fractions and raft (R)
fractions were pooled and immunoblotted for the indicated proteins. (D)
Activated forms of Jak2, STAT5, and MAPK were also increased in the raft
fractions after Epo stimulation. All westerns were repeated at least in duplicate.

Lipid rafts are required for EpoR signaling. Given that EpoR activation
triggers formation of rafts enriched in signal effectors, we next investigated
whether rafts are necessary for receptor signaling by way of raft microdomain
disruption. Cholesterol depletion of UT7 cell membranes with methyl-β-
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cyclodextrin (MBCD) disrupted raft integrity and completely extinguished Epo
induced phosphorylation of STAT5, the primary downstream transcription factor
(Fig 16A). To determine if secondary Epo signaling pathways were also affected
by MBCD treatment, we probed UT7 cells for P-MAPK (mitogen-activated protein
kinase). Indeed, pretreatment of cells with MBCD abrogated activation of MAPK
with Epo stimulation. The PI3K/Akt pathway is not activated by Epo in UT7 cells,
therefore, to investigate effects on this signaling pathway, we utilized the
UT7/Epo cell line which displays Akt activation upon Epo stimulation (Fig 16B).
Pretreatment with MBCD completely extinguished activation of Akt by Epo,
thereby confirming that all Epo signaling pathways are impaired by raft disruption.
To verify that MBCD treatment only affected signaling pathways localized to lipid
rafts, we treated UT7 cells with the cell permeable phorbol 12-myristate 13acetate (PMA), which is not directly dependent on membrane receptor activation,
and induces UT7 differentiation in part through the activation of MAPK.
Pretreatment of UT7 cells with MBCD prior to PMA stimulation did not affect
activation of MAPK as evidenced by enzyme phosphorylation (Fig 16C). These
data indicate that lipid raft integrity is essential for EpoR signaling, whereas nonreceptor or non-raft signaling pathways are preserved and independent of raft
integrity. To confirm that abrogation of EpoR/STAT5 signaling by MBCD is not
specific to this compound, we repeated the above experiment using the
cholesterol intercalating agent, nystatin, a less effective but alternative method to
interfere with raft assembly and dynamics. Similar to our findings with MBCD,
treatment with nystatin decreased STAT5 phosphorylation in response to Epo
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Figure 16. Raft integrity is necessary for Epo-induced signaling. (A) UT7 cells
were starved for 2h then pretreated with MBCD for 30min and stimulated with
3U/ml Epo for 10min; lysates were immunoblotted with the indicated antibodies.
(B) UT7/Epo cells were starved for 2h then pretreated with MBCD for 30min and
stimulated with 3U/ml Epo for 10min. Lysates were immunoblotted with P-Akt.
The findings show abrogation of Akt phosphorylation following MBCD
pretreatment. (C) UT7 cells were pretreated with MBCD for 30min, then
stimulated with PMA for 30min. (D) UT7 cells were starved for 2h then
pretreated with Nystatin for 30min and stimulated with Epo for 10min.
Immunoblots for phospho-STAT5, STAT5, and β-actin antibodies with
densitometry analysis. All westerns are representative of at least 2 independent
experiments.

stimulation (Fig 16D); providing further support for the importance of lipid rafts in
EpoR signal transduction.

Raft disruption attenuates Epo-induced P-STAT5 induction in
primary erythroid progenitors. To confirm raft integrity is critical to EpoR
signaling in primary erythroid progenitors, we next assessed the effect of raft
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disruption by MBCD on Epo induced STAT5 phosphorylation by flow cytometry in
bone marrow derived erythroid precursors from a normal donor. After a 2h
starvation, BM-MNCs were pretreated with MBCD either with or without Epo.
Cells were permeabilized and stained with antibodies to CD71, CD45, and
phospho-STAT5. Epo-responsive erythroid progenitors were identified by gating
on the CD45 dim population of CD71+ cells (Fig 17A), and phospho-STAT5 mean
fluorescent intensity (MFI) was determined (Fig 17B). Treatment with MBCD
significantly decreased STAT5 phosphorylation in response to Epo stimulation
(Fig 5B; P=0.01). Flow histograms show a marked shift consistent with a marked
reduction in phospho-STAT5 MFI (Fig 17C). These findings confirm that
membrane raft integrity is critical to the fidelity of EpoR signaling in primary
erythroid precursors.

Recruitment of EpoR into lipid rafts is abrogated by Rac1 and RhoA
inhibition. Rho GTPases are key regulators of intracellular actin dynamics, and
are involved in T-cell receptor trafficking into lipid rafts upon receptor
stimulation.122 We therefore investigated whether GTPases were also involved in
EpoR recruitment into membrane rafts after Epo stimulation. UT7 cells were
pretreated with a Rac1 inhibitor prior to Epo stimulation, demonstrating that
inhibition of Rac1 suppressed recruitment of the receptor into raft fractions (Fig
18A). We next investigated the effects of RhoA family GTPase inhibition by
pretreating cells with the Rho-associated protein kinase, ROCK, inhibitor, Y27632; again showing that EpoR recruitment was blocked (Fig 18B). These
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Figure 17.
Cholesterol depletion attenuates Epo-induced STAT5
phosphorylation in primary erythroid progenitors. (A) Bone marrow mononuclear
cells from a normal donor were isolated then stained with CD71:APC,
CD45:FITC, and P-STAT5:PE. CD71Hi/CD45dim cells representing erythroid
progenitors were gated. (B) Graphic comparison of geometric mean florescence
intensities, mean ± standard error from 3 independent experiments.
(C)
Representative flow histogram showing shift in phospho-STAT5 florescence
intensity in primary erythroid progenitors treated with Epo with or without MβCD.

findings suggest that Rac1 and RhoA GTPase activation is critical in the
redistribution of receptor into membrane fraction upon ligand binding.

Discussion
To our knowledge, these are the first data to provide evidence that the
EpoR translocates into lipid raft microdomains of the plasma membrane upon
ligand engagement (Fig 14). Moreover, receptor recruitment into rafts appears
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Figure 18. Recruitment of EpoR into lipid rafts is dependent on Rac1 and RhoA
GTPase activation. (A) Raft fractions were isolated from UT7 cells pretreated
with 100nM Rac1 inhibitor for 1hr prior to Epo stimulation then immunoblotted for
EpoR with corresponding quantitation. (B) Raft fractions were isolated from UT7
cells pretreated with 100uM ROCK inhibitor (Y-27632) for 1h prior to Epo
stimulation then immunoblotted for EpoR with corresponding densitometry
analysis. Westerns are representative of two independent experiments.

necessary for EpoR signal fidelity and consequent activation of STAT5. In
unstimulated cells, the EpoR resided largely in non-raft membrane fractions,
which may serve to minimize the potential for ligand-independent interaction with
signaling intermediates. Upon growth factor engagement, the receptor was
recruited into lipid rafts accompanied by the incorporation of signaling effectors
necessary to phosphorylate sites on the receptor tail and initiate signal
transduction, including both the JAK2 and Lyn kinases, in addition to the principal
downstream transcription factor, STAT5 (Fig 15). Interestingly, CD45, a
transmembrane protein tyrosine phosphatase that serves to extinguish receptor
signaling by dephosphorylating JAK2 and the EpoR, was constitutively localized
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within membrane rafts in unstimulated cells, whereas upon stimulation with Epo,
re-partitioned exclusively into non-raft fractions. These dynamic changes in
CD45 partitioning should serve to optimize receptor signaling upon ligand
engagement, while restricting the potential for ligand-independent effector
activation in the absence of the growth factor. Moreover, these ligand induced
changes in the redistribution of the EpoR and its effectors appear necessary for
erythropoietin signal fidelity. Disruption of rafts by cholesterol depletion
abrogated Epo-induced STAT5 phosphorylation in both UT7 cells and normal
erythroid precursors (Figs 16,17), whereas non-receptor initiated activation of
MAPK by PMA remained intact. Intercalation of membrane cholesterol by
nystatin treatment also attenuated Epo signaling, indicating that receptor
integration into rafts is critical and perhaps obligatory for EpoR signaling.
The subcellular mechanisms responsible for ligand induced changes in
raft and receptor dynamics may involve G-protein controlled cytoskeletal
changes. The dependence of EpoR signaling on lipid raft recruitment and
assembly is analogous to the changes observed in lymphocytes after ligation of
the T-cell or B-cell receptors.122 Within minutes of ligand engagement of the Tcell receptor, receptor subunits translocate into lipid rafts from their residence in
non-raft membrane domains (Figure 15B). T-cell receptor re-distribution is
controlled by G-protein coupled actin polymerization involving activation of Rac
GTPases, a hematopoietic specific member of the Rho superfamily that regulates
the organization, dynamics and function of the actin cytoskeleton.122,140
Conditional knock-out of Rac2 was recently shown to block early stages of
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erythropoiesis in the bone marrow in murine models, suggesting that Rac2 may
be a candidate molecular regulator of the observed Epo-induced changes in
membrane dynamics.159,161 Our studies show that inhibition of either Rac1 or
RhoA GTPases suppresses EpoR translocation into membrane raft domains.
Defects in GTPase activation therefore could adversely affect receptor signaling
in select pathologic conditions. In myelodysplastic syndromes, for example, Rac
activation is impaired in neutrophils and CD34+ progenitors,197 accompanied by
impaired lipid raft formation and a corresponding reduction in the generation of
reactive oxygen species after fMLP stimulation in granulocyte-macrophage
colony-stimulating factor primed neutrophils.198 Abnormalities in raft assembly in
erythroid progenitors might also underlie the previously described abnormalities
in EpoR signaling in MDS which warrants further investigation.49 Overall, our
findings indicate that ligand engagement of the EpoR initiates dynamic changes
in raft assembly and composition that bring the receptor and its effectors into
spacial and temporal proximity within a discrete membrane compartment that
facilitates activation of the signaling cascade. Development of strategies that
enhance raft assembly and EpoR incorporation may be an attractive strategy to
improve erythropoiesis in hematologic disorders with impaired erythropoietic
response.

Methods

Reagents and antibodies. CD71:APC, P-STAT5(Y694):PE, and CD45:FITC

81

conjugated antibodies used for flow cytometry and anti-CD45 used for western
blotting were all purchased from BD Biosciences (San Jose, CA). STAT5, Lyn,
Akt, P-Jak2, and Jak2 antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The principal EpoR antibody used in this study
was purchased from Santa Cruz Biotechnology (M-20). To confirm immunospecificity of EpoR localization (Fig 15A) we also included Abcam mouse mAb
(MM-0031-6G7), Abcam goat polyclonal, and Amgen (Thousand Oaks, CA) A82
EpoR antibodies. ROCK inhibitor, Y-27632 dihydrochloride monohydrate,
cholera toxin B (CTB) HRP conjugate, methyl-beta-cyclodextran, Nystatin, and
PMA were purchased from Sigma-Aldrich (St. Louis, MO). P-MAPK, MAPK, and
anti-P-STAT5 (Y694) for westerns were purchased from Cell Signaling
Technology (Danvers, MA). P-Akt, Alexa Fluor® 488 goat anti-rabbit IgG, and
Vybrant® Lipid Raft Labeling Kit were ordered from Invitrogen (Carlsbad, CA).
Recombinant human Epo (Epo) was purchased from Stemcell Technologies
(Vancouver, BC, Canada). Rac1 Inhibitor was purchased from EMD Millipore
(Billerica, MA).

Cell lines and bone marrow cultures. The human leukemic cell line,
UT7, was obtained from ATCC (Gaithersburg, MD). UT7 cells were maintained
in α-MEM medium supplemented with 20% fetal bovine serum (FBS), 1%
penicillin/streptomycin solution, and 5ng/ml GM-CSF. UT7/Epo cells were
maintained in IMDM medium supplemented with 10% FBS, 1%
penicillin/streptomycin solution, and 1U/mL Epo. After overnight starvation, cells
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were stimulated with Epo at a concentration of 3U/mL. For Rac1 and ROCK
inhibitor experiments, cells were pretreated for 1h with 100nM and 100uM,
respectively, before stimulation with Epo. Low-density mononuclear cell (MNC)
fractions were isolated from heparinized bone marrow aspirates from healthy
volunteers purchased from Lonza Walkersville Inc. (Walkersville, MD) using
standard density gradient centrifugation over Ficoll-Paque Plus (GE Healthcare,
Little Chalfont, United Kingdom), followed by washing and resuspension in
Iscove’s Modified Dulbecco Medium (IMDM) supplemented with 10% fetal bovine
serum, penicillin, and streptomycin.
Erythroid progenitors at the burst-forming unit–erythroid (BFU-E) stage of
differentiation were grown in cytokine-defined IMDM, similar to previous
studies.199 Briefly, 2 X 105 MNC per mL were plated in Complete Methocult®
medium (StemCell Technologies, Vancouver, BC, Canada) supplemented with
10% FBS and 3 U/mL erythropoietin. Plates were incubated at 37ºC in a 5%
CO2 air mixture in a humidified incubator for 14 days. BFU-E were identified
using an inverted microscope, aspirated by pipette, washed twice in PBS then
resuspended in IMDM for immunofluorescence studies.

Immunoblotting. Cells were starved in 0.5% FBS containing medium for
2h prior to 30 min pre-incubation with 10mM MBCD or 50µg/ml nystatin, or
stimulation with 3U/ml Epo (10 min) or 100ng/ml PMA (30 min). For RAC and
ROCK inhibitor experiments, cells were pretreated for 1h prior to Epo stimulation.
Cells were washed 3x in cold PBS and lysed in 1X RIPA buffer containing 250µM
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NaVO4, 2µg/ml aprotinin, 2µg/ml leupeptin, 0.2µg/ml pepstatin A, and 500µM
PMSF. Sample buffer was added to cell lysates and 100µg of protein was
separated using SDS-PAGE. Proteins were transferred to PVDF membranes
and immunoblotted with the indicated antibodies. Membranes were developed
using ECL or ECL Plus according to manufacturer’s protocols (GE Healthcare,
Piscataway, NJ).

Flow cytometry. Bone marrow from normal donors was purchased from
Lonza (Walkersville, MD). BM-MNCs were isolated using Ficoll-Paque PLUS
(GE Healthcare, Piscataway, NJ) and starved for 2h in 0.5% FBS containing
IMDM medium. The cells were then pretreated with 10mM MBCD for 30min and
stimulated with 3U/ml Epo for 10min. They were immediately washed 3x in cold
Staining Buffer (BD Biosciences San Jose, CA), fixed for 10min at 37°C in
Cytofix (BD), then permeabilized for 30min on ice with Perm Buffer III (BD). Cells
were stained with CD71:APC, CD45:FITC, and P-STAT5:PE conjugated
antibodies. Cells were washed with Staining Buffer and analyzed on a
FACScalibur flow cytometer. Primitive erythroid cells were captured in CD71Hi
and CD45Dim gated population.

Lipid raft isolation. Lipid Rafts were isolated as previously
described.105,198 Briefly, UT7 cells were washed 2x with cold PBS then lysed in
0.75% Triton X-100 in TNE Buffer [TNE buffer composed of 25mM Tris pH7,
150mM EDTA, 1mM DTT, 150mM NaCl, and 1 Complete EDTA-free protease
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inhibitor tablet from Roche (Indianapolis, IN) per 20ml buffer]. Cells were passed
through a 27G needle several times and incubated on ice for 5min. Two hundred
microliters of lysate were mixed with 400µL of 60% Optiprep (Sigma-Aldrich, St.
Louis, MO) and pipetted into an ultracentrifuge tube. Decreasing percentages of
Optiprep ( 35%, 30%, 25%, 20%, and 0%) were loaded on top of each other and
the tubes were spun at 20000rpm for 20h in a Beckman Coulter (Fullerton, CA)
Optima L-90K ultracentrifuge. Fractions were pipetted off one by one and used
for dot and western blotting.

Dot blots. Five or ten microliters of fractionated cell lysates were pipetted
directly onto nitrocellulose membrane. The membranes were allowed to dry then
washed briefly in PBS. They were then blocked in 0.3% Tween20 PBS for 30min
and incubated in cholera toxin B:HRP conjugated antibody overnight. The blots
were washed 3x in 0.3% Tween20 PBS and developed with ECL.

Immunofluorescence. Starved UT7 cells (0.5% FBS supplemented αMEM medium) were stained with Vybrant® Lipid Raft Labeling Kit according to
manufacturer’s protocol, treated with 3U/ml EPO for 10min at 37°C and fixed with
Cytofix (BD Biosciences San Jose, CA ) for 10m at 37°C. Cells were then
cytospun and stained with EpoR antibody at a 1:50 dilution for 1hr at 37°C,
washed in PBS and stained 1:500 with Alexa Fluor® 488 goat anti-rabbit IgG for
1hr at 37°C. Cells were then mounted using ProLong ® AntiFade reagent with
DAPI (Invitrogen, Carlsbad, CA) and cover slip placed on top. Micrographs were
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taken using a Leica TCS SP5 AOBS Laser Scanning Confocal microscope (Leica
Microsystems, Germany). BFU-E colonies isolated from progenitor cultures from
a normal donor were washed 2X then starved in 0.5% FBS supplemented IMDM
medium for 2h. They were then stained with EpoR and Alexa Fluor® 488 goat
anti-rabbit IgG as above. The cells were then washed and stained with Vybrant®
Lipid Raft Labeling Kit according to manufacturer’s protocol. Cells were
resuspended in 1ml medium and stained with 1µg/ml Hoechst stain (Invitrogen,
Carlsbad, CA). Micrographs of the untreated cells were taken by confocal
microscopy then 3U/ml of Epo was added to the plate and micrographs from
stimulated cells were taken 5-20min after Epo treatment.

Immunofluorescence image analysis. Photomicrographs were obtained
using a Leica TCS SP5 AOBS laser scanning confocal microscope at zoom
through a 20X/0.5NA or 63X/1.40NA Plan Apochromat oil immersion objective
lens (Leica Microsystems, Germany). 405 Diode, Argon 488, and HeNe 543 or
594 laser lines were applied to excite the flurophores and tunable emissions
were used to minimize crosstalk between fluorochromes. Gain, offset, and
pinhole settings were identical for all samples within the treatment group. Image
sections were collected at either 0.2 µm (for 3D reconstructions) or at 0.5µm
were captured with photomultiplier detectors and maximum projections were
prepared with the LAS AF software version 2.1.0 (Leica Microsystems, Germany).
In some cases, 4X zoom was applied when acquiring images. Intensity and
aggregate analysis were performed using Image Pro Plus version 6.2 (Media
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Cybernetics, Inc., Silver Springs, Maryland). Identical threshold settings and
measurement parameters were used to generate the mean intensity and area
data. Aggregates were defined as an object within the cell that has an intensity
value of at least 20 and an area between 3 and 600 pixels. Three dimensional
isosurface renderings were prepared with Imaris software version 5.5.3 (Bitplane
Inc., Zurich, Switzerland).

Statistical analysis. Numerical data are expressed as mean ± standard
error of the mean. Statistical analyses were performed using the Student t test
(2-tailed for equal variances). P values < 0.05 were considered significant.
Pearson’s correlation analysis for colocalization was performed using Definiens
Developer version 1.5 (Definiens AG, Munich, Germany).
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CHAPTER 3
Lenalidomide induces Lipid Raft Formation and F-Actin Polymerization

Introduction
Bone marrow progenitors from patients with MDS display diminished
activation of STAT5 in response to Epo stimulation despite normal or elevated
levels of endogenous serum Epo and similar EpoR membrane density compared
to normal counterparts.49 Our laboratory reported that the EpoR resides within
plasma membrane microdomains known as lipid, or membrane rafts, which is
critical to EpoR signal competence (Chapter 2).200 Epo induced the formation
and aggregation of lipid rafts, as well as the recruitment of key signaling
intermediates such as EpoR, Jak2, STAT5, and Lyn kinase. Furthermore,
receptor engagement of the Epo ligand triggered the translocation of the signal
attenuating transmembrane tyrosine phosphatase, CD45, to non-raft domains,
ultimately potentiating signal capacity.200 Disruption of rafts by membrane
cholesterol depletion inhibited Epo induced activation of STAT5 in both erythroid
cell lines and primary bone marrow erythroid progenitors, thereby confirming the
critical role of raft integrity in cellular Epo response.200 Furthermore, inhibition of
Rho and Rac GTPases, important regulators of the actin cytoskeleton, blocked
recruitment of EpoR into the raft fractions, indicating a critical role for these
proteins in the coordination of EpoR membrane domain localization.200
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GTPases are activated by immunomodulatory agents (IMiDs) which in turn
trigger assembly of the immune synapse in T- and NK-cells.127,128 LEN enhances
erythroid progenitor expansion, potentiates in vitro colony forming capacity in
response to Epo, and augments Epo induced receptor signaling through
mechanisms that have not as yet been characterized.46-48 Approximately 75% of
lower risk, del(5q) MDS patients will respond to LEN acquiring red blood cell
transfusion independence, hemoglobin normalization, and decrease in the
del(5q) clone.1,6 This occurs through direct suppression of the del(5q) clone via
inhibition of the haplosufficient cell cycle regulatory phosphatases, Cdc25c and
PP2A, resulting in G2/M cell arrest and apoptosis.51 In non-del(5q) MDS,
erythropoietic rescue occurs in approximately 25% of patients in the absence of
cytotoxicity to the MDS clone, as evidenced by a decrease in bone marrow
apoptotic fraction in responding patients, suggesting erythropoietic potentiating
effect. In their report, Ebert et al. showed that LEN treatment restored
expression of the underexpressed erythroid differentiation gene set in responding
patients, indicating that LEN can improve inherent limitations in EpoR
transcriptional response in MDS.50 We hypothesize that there is a decrease in
lipid raft density in MDS patients and that LEN acts at a proximal level in EpoR
signaling by recruiting signaling intermediates and EpoR into aggregated, active
signaling raft platforms. And, that these effects are dependent on the activation
of the Rho kinase, ROCK.
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Results
LEN induces lipid raft formation. We previously showed that treatment
of the erythroleukemia cell line, UT7, with recombinant human erythropoietin
(rhEpo) stimulated rafts within minutes of growth factor exposure.200 We next
investigated the effects of LEN on raft formation and aggregation. To assess
this, we treated UT7 cells with 1µM LEN for 1h. Lipid rafts were isolated by
ultracentrifugation and fractions were dot blotted for GM-1 detection (Figure
19A). GM-1 is a raft constituent ganglioside and its fractionation and membrane
localization is used as a marker of lipid rafts.105,131,132 The observed increase in
GM-1 positive membrane fractions (fraction 2) indicates that LEN treatment
increased membrane lipid rafts, and this increase was more than that observed
with rhEpo stimulation (Figure 19A). To confirm this finding, we next analyzed
raft aggregation by confocal microscopy in UT7 cells after LEN treatment. We
found a marked increase in the number and size of lipid rafts as ascertained by
GM-1 detection (Figure 19B). These results demonstrate that LEN is able to
stimulate raft formation and raft aggregation in the absence of cytokine or
receptor stimulation.

LEN recruits signal effectors into raft fractions. Our prior studies
showed that in addition to inducing raft formation and aggregation, rhEpo
induced the recruitment of EpoR and signal intermediates Jak2, STAT5, and Lyn
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Figure 19. LEN induces the formation of membrane lipid rafts. (A) Dot blot
detection of GM-1 membrane fractionation in UT7 cells treated with 1U/ml
erythropoietin or 1µM LEN for 1hr. Rafts are located in fraction 2 and non-rafts
fractions are in 4-6. (B) Immunofluorescence of UT7 cell rafts in red showing a
marked accumulation after LEN treatment.

kinase into the raft platforms. Treatment with rhEpo also sequestered the
negative regulator and transmembrane protein, tyrosine phosphatase CD45, out
of the raft fractions, thereby potentiating fidelity of the EpoR signal. To determine
whether LEN treatment effected raft constituents, we treated UT7 cells and
isolated both the raft fractions (fraction 1-3) and non-raft fractions (fractions 4-6)
after ultracentrifugation (fractions were also confirmed by dot blot, data not
shown). These fractions were then probed by western blot (Figure 20). We
found that LEN readily induced the recruitment of EpoR into lipid raft fractions
after 1hr of drug exposure (Figure 20). We utilized the Santa Cruz (M-20) EpoR
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Figure 20. LEN treatment induces recruitment of EpoR and signaling effectors
into lipid rafts. Western blot of fractionated rafts (red boxes) and non-raft
fractions. LEN induces recruitment of EpoR, Jak2, and Stat5 into the raft
fractions while displacing the negative phosphatase regulator, CD45. Lyn kinase
serves as a marker for lipid raft fractionation, although no redistribution was
observed after LEN treatment.

antibody in these experiments based on previous studies, including ours,
validating its specificity.81,200 Furthermore, both Jak2 and STAT5 showed
increased fractionation with GM-1 after LEN treatment indicating recruitment of
signaling effectors into discrete signaling platforms, similar to that described after
T-cell activation.109,121,122,200 Additionally, we found that LEN treatment also
partially redistributed CD45 out of the raft fractions further promoting signal
efficiency. Although Lyn kinase fractionation did not change, its partitioning is
another method by which lipid raft fractions (fractions 1-3) may be ascertained.
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ROCK inhibition blocks LEN Induced raft formation. We previously
demonstrated that rhEpo induction of lipid rafts was dependent on the Rac
GTPases. Inhibition of both the Rho kinase, ROCK, and Rac GTPase inhibited
recruitment of EpoR into the raft fractions after Epo stimulation. We wished to
determine whether ROCK was similarly involved in LEN induced raft formation.
UT7 cells were treated with LEN either with or without pretreatment with 100µM
ROCK inhibitor, Y-27632, for 30m. Pretreatment of cells with Y-27632 inhibited
the induction of lipid rafts by LEN as shown by GM-1 dot blot detection (Figure
21A). These data were further confirmed by confocal microscopy (Figure 21B),
and suggest that the induction of rafts by LEN is dependent on the ROCK kinase.

Figure 21. LEN induced raft formation is ROCK dependent. (A) Dot blot
detection of GM-1 in UT7 cells treated with LEN either with or without ROCK
inhibitor, Y-27632 (ROCKi), pretreatment. Rafts are located in fractions 1 and 2,
while non-raft fractions are 4-6. (B) Immunoflorescence of rafts (red), nuclei
(blue), and merged image showing inhibition of LEN induced raft formation with
ROCKi pretreatment.
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ROCK inhibition blocks LEN induced F-actin polymerization. The
immune synapse in T and NK cells is formed through extensive lipid raft
aggregation initiated by F-actin polymerization, a process that is regulated by the
Rho GTPase, ROCK, and LIM kinase (LIMK).127-129 Rho activates actin
polymerization through the Wiscott-Aldrich Syndrome protein (WASp), which in
turn activates the Arp2/3 complex proteins that are responsible for promoting
actin polymerization.157 Furthermore, Rho activates the myosin light chain (MLC)
promoting actin assembly, while ROCK inactivates the MLC negative regulatory
phosphatase.127,143,147,151 Lastly, LIMK kinase phosphorylates cofilin. When
cofilin is phosphorylated, it is no longer able to bind to actin and prevent
polymerization.150 Disruption of the Rho/ROCK/LIMK pathways resulted in
decreased raft accumulation and recruitment of the T-cell receptor, with
consequent impaired immunological synapses.127-129 We sought to determine
whether LEN induced actin polymerization in UT7 cells to foster raft assembly
and whether this process was similarly dependent on ROCK. Cells were treated
and stained with phalloidin and analyzed by confocal microscopy (Figure 22).
LEN treatment induced actin filament polymerization that was inhibited by
pretreatment with the ROCK inhibitor, Y-27632. Analogous to the formation of
the immunological synapse, ROCK dependent F-actin assembly is likely
responsible for the coalescence of rafts and EpoR signaling components in
erythroid cells.
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Lenalidomide induces raft formation in MDS erythroid progenitors.
Previous reports have shown that fLMP stimulated granulocyte–macrophage
colony stimulating factor (GM-CSF) primed MDS neutrophils have decreased raft
density associated with decreased production of reactive oxygen species.198

Figure 22. LEN induces actin polymerization that is blocked by ROCK inhibition.
Phalloidin (green) was used to detect actin polymerization. LEN treatment
induced actin polymerization, but was inhibited by pre-treatment with ROCK
inhibitor (ROCKi). DAPI (blue), last panel is merged image.

Furthermore, Rac activation is reported to be impaired in both neutrophils and
CD34+ progenitor cells in MDS.197 Therefore, we sought to determine whether
an impairment in lipid raft assembly limits membrane raft density in primary MDS
erythroid progenitors to contribute to diminished Epo responsiveness.198 Primary
bone marrow mononuclear cells were isolated from 11 non-del(5q) MDS patients
consented on IRB approved research protocols and from 3 normal donors
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purchased from Lonza Walkersville. Cell were treated with LEN then cytospun
and stained with CD71 and c-Kit antibodies, as well as for lipid rafts. Erythroid
progenitor cells were identified as dual CD71 and c-Kit+; the number of raft
clusters was determined by confocal microscopy. Mean number of membrane
raft clusters in MDS erythroid progenitors was decreased compared to normal
volunteers (p=0.129) (Figure 23). This deficiency was partially rescued with LEN
treatment. Although we did not reach statistical significance, we suspect that if
we increased the number of samples used, that statistical significance may be
achieved. These results provide a novel mechanism of action for LEN in primary
non-del(5q) MDS cells and warrants study in a larger data set.

Figure 23. LEN induces rafts in deficient non-del(5q) MDS primary erythroid
progenitors. Immunofluorescence of raft density in primary normal and nondel5q MDS bone marrow erythroid progenitors (CD71+, c-Kit+). DAPI (blue),
CD71 (green), c-kit (pink), rafts (red). Primary MDS progenitors show decreased
raft clusters compared to normal controls, however, raft formation is induced with
LEN treatment.
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Discussion
The data shown here provide new insight as to abnormalities in the EpoR
signaling platform that may underlie the impaired responsiveness of erythroid
precursors to Epo in MDS. We show that EpoR signal fidelity is dependent upon
proper and adequate lipid raft assembly in the plasma membrane. In MDS
erythroid precursors, we found that raft formation is deficient, and importantly,
that LEN augments Epo-induced erythroid expansion. Our findings reveal that
LEN is able to promote lipid raft formation and the recruitment of EpoR into the
raft microdomains. Additionally, Jak2 and STAT5 are recruited to the rafts
compartments while the tyrosine phosphatase CD45 is re-partitioned out of raft
fractions upon LEN exposure. LEN induced raft assembly that was dependent
upon F-actin polymerization, a process which was dependent on the Rho kinase,
ROCK. GTPases are known to coordinate reorganization of the actin
cytoskeleton, which is responsible for raft coalescence and the formation of the
immune synapse in T-cell activation.127-129
The actin cytoskeleton has important roles in cell proliferation and
differentiation, and aberrancies in actin polymerization have been implicated in
the disease pathogenesis of hematological malignancies. Recent findings have
shown that the unconventional Rac activating guanine nucleotide exchange
factor (GEF), DOCK4, is decreased in MDS patients compared to age-matched
controls. DOCK4 is a member of the CDM (C. elegans Ced-5, mammalian
DOCK180 and D. melanogaster myoblast city) family of proteins which are
known regulators of adheren junctions and cell migration. The DOCK4 promoter
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is hypermethylated in MDS causing gene silencing and decreased protein
expression.199 Of note, DOCK4 is localized to chromosome 7q31, and deletions
or translocations involving this site are associated with poor prognosis in MDS
and AML. Recent data presented at the 2012 American Society of Hematology
annual meeting showed that silencing of DOCK4 in MDS was associated with
diminished F-actin polymerization.203 Furthermore, decreased DOCK4 was
associated with increased erythrocyte fragility, whereas knockdown of DOCK4 in
primary progenitor cells led to lineage specific apoptosis of erythroid progenitors,
features shared by MDS progenitors. These findings provide a plausible
pathobiological rationale for the ineffective erythropoiesis in MDS in which
intrinsic cytoskeletal abnormalities arising from decreased DOCK4 initiated
polymerization of actin impairs lipid raft assembly and growth factor receptor
incorporation. As a consequence, cytokine signal capacity and cell survival are
diminished. Rac GTPase dependent raft integrity, which in our investigations is
partially rescued by LEN, further supports this notion. The effects of LEN on
DOCK4 expression and activity warrants further investigation.
Although LEN is known to activate GTPases, the mechanism by which this
occurs is unknown.128 Recent findings demonstrate that IMiDs bind to the
cereblon E3 ubiquitin ligase complex to inhibit ligase function, which appears
responsible for the teratogenicity of thalidomide as well as the anti-proliferative
effects of both LEN and thalidomide in multiple myeloma. Furthermore, we
recently reported that LEN inhibits the ligase activity of MDM2.204 Inhibition of
MDM2 auto-ubiquitination stabilizes the protein, permitting binding to and
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degradation of p53 in del(5q) clones.204 These findings suggest that LEN may
have broader E3 ligase inhibitory effects. It is possible that LEN may activate
GTPases via inhibition of the E3 ligases responsible for their degradation.
Currently, several ligases are recognized to ubiquitinate RhoA, including SMAD
ubiquitination regulatory factor 1, SMURF1 and the CRL3 complex (Cullin-RING
ubiquitin ligase). The HECT ligase, HACE1, has recently been reported to be
involved in the ubiquitination and degradation of Rac1. Additional investigations
are warranted to determine whether these ligases are also inhibited by LEN.
These experiments will determine whether E3 ligase inhibition is responsible for
GTPases activation and consequent actin cytoskeletal reorganization that
augments EpoR signaling by modulating raft assembly and composition.

Methods

Reagents and cells. UT7 cells were maintained in alpha-MEM
supplemented with 20% FBS, 1% penicillin/streptomycin solution, and 5ng/ml
GM-CSF in a humidified incubator with 5% CO2. Bone marrow mononuclear
primary cells were isolated from 11 MDS patients consented on IRB approved
protocols using Ficoll-Paque (GE Healthcare, Little Chalfont, UK) method and
from 3 normal donors purchased from Lonza Walkersville Inc (Walkersville, MD).
LEN was purchased from Fisher Scientific (Pittsburgh, PA). CT-B:HRP was
purchased from Sigma-Aldrich (St. Louis, MO) EpoR, Jak2, Stat5, CD71, c-Kit,
and Lyn antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
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CA). CD45 antibody was purchased from BD Biosciences (San Jose, CA).
Secondary antibodies were purchased from Life Technologies Corporation
(Invitrogen, Carlsbad, CA) ProLong® Anti-fade reagent with DAPI was
purchased from Life Technologies (Invitrogen). ROCK inhibitor, Y-27632
dihydrochloride monohydrate, was purchased from Sigma-Aldrich.

Lipid raft isolation. Lipid rafts were isolated as previously described.200
Briefly, cells were lysed in 0.75% Triton X-100 in TNE buffer [25mM Tris pH7,
150mM EDTA, 1mM DTT, 150mM NaCl, and 1 Complete EDTA-free protease
inhibitor tablet from Roche (Indianapolis, IN) per 20ml buffer]. Cells were then
passed through a 27G needle and left on ice for 5min. Lysates were then
pipetted below a decreasing concentration gradient of Optiprep purchased from
Sigma-Aldrich. Samples were ultracentriguged at 20000rpm for 20h in a
Beckman Coulter (Fullerton, CA) Optima L-90K ultracentrifuge. Fractions were
pipetted off one by one and used for either western blotting and/or dot blotting.

Western blotting. Fractions isolated after raft isolation were resolved by
SDS-PAGE then transferred to PVDF membranes. The membranes were
blocked for 30 min in 5% dry milk solution in PBST (PBS with 0.1% Tween 20)
and incubated with the indicated antibodies. Membranes were developed using
ECL or ECL+ according to manufacturer’s protocol (GE Healthcare, Little
Chalfont, UK).
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Dot blotting. Five microliters of each fraction isolated from
ultracentrifugation was pipetted onto a nitrocellulose membrane. The membrane
was then washed in PBS and blocked for 30min in 0.3% PBS-Tween20 solution.
Membranes were then incubated with CT-B:HRP overnight then washed three
times in PBS with 0.3% PBS Tween20. Membranes were developed using ECL
according to manufacturer’s protocol.

Immunofluorescence. Raft immunofluorescence was performed as
previously described.200 Briefly, treated cells were stained with Vibrant Lipid Raft
Labeling kit (Invitrogen) per manufacturer’s protocol, then cytospun at 450rpm for
5 min. Slides were then fixed with BD Cytofix (BD Biosciences) for 10 min at
37°C. Slides were washed in PBS and a drop of ProL ong® Anti-fade reagent
with DAPI was added with a cover slip. Micrographs were taken using a Leica
TCS SP5 AOBS Laser Scanning Confocal microscope (Leica Microsystems,
Germany). For F-actin staining, cells were treated, then fixed and cytospun.
Slides were permeabilized in 0.5% Triton-X for 5min at room temperature then
washed and blocked in 2% BSA-PBS. Cells were then stained with Alexa Fluor
488 phalloidin according to manufacturer’s protocol (Invitrogen). Cells were
washed, then ProLong® Anti-fade reagent with DAPI was added with a coverslip,
and micrographs were taken on the Leica TCS SP5 AOBS Laser Scanning
Confocal microscope. For the primary cell immunofluorescence experiments,
rafts were stained as described above. Before adding DAPI, cells were blocked
and stained with CD71 and c-Kit antibodies for 1h at room temperature. Slides
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were then washed and incubated in secondary antibody (1:1000) for 1hr at room
temperature. Micrographs were taken by confocal microscopy.
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CHAPTER 4
Lenalidomide Stabilizes EpoR Expression through Inhibition of the E3
Ubiquitin Ligase, RING Finger Protein 41 (RNF41)
A note to the reader: Portions of this work have been previously published in
the journal Blood, Basiorka et al. 2011. 118:2382a and Basiorka et al. 2012
120(21):3455a, and USF Honors College Undergraduate Thesis, Ashley
Basiorka, 2012, and have been reproduced here with permissions.

Introduction
Lenalidomide (LEN), restores defective erythropoiesis and red blood cell
transfusion independence in approximately 25% of non-del(5q) MDS patients. Gene
expression profiling performed by Ebert et. al. showed that LEN responders
displayed inherently lower expression levels of erythroid specific genes that were
restored by treatment with LEN.50 Our investigations showed that LEN acts to
enhance EpoR signal capacity to increase transcriptional response to Epo ligand
receptor engagement. The latter is achieved at least in part through LEN’s
potentiating effect on lipid raft assembly accompanied by recruitment of the EpoR
and key signaling intermediates into the raft microdomains (Chapter 3).
Recent investigations revealed that both thalidomide and LEN bind to and
inhibit the function of the cereblon E3 ubiquitin ligase complex, which has been
implicated in LEN antiproliferative effects in multiple myeloma, and the teratogenicity
of thalidomide.39,44,168,169 Our laboratory and colleagues recently reported that LEN
binds to and inhibits the function of another E3 ubiquitin ligase, the murine double
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minute-2 protein (MDM2).175 LEN inhibits auto-ubiquitination of MDM2 to stabilize
the protein and foster its binding to and degradation of p53. Because EpoR turnover
is regulated by ubiquitination and proteasomal degradation, we evaluated the effects
of LEN on the E3-ubiquitin ligase, RNF41, which regulates steady state or ligand
independent, Janus kinase (JAK2) associated Type I receptor internalization.87 We
hypothesized that LEN upregulates JAK2/EpoR expression through inhibition of
RNF41, thereby enhancing JAK2 competent receptor signaling.

Results

Lenalidomide upregulates EpoR protein expression. To determine the
effect of LEN on EpoR expression, UT7 cells were treated with increasing
concentrations of LEN for 1hr. Western immunoblot showed that LEN increased
EpoR protein expression in a dose dependent manner (Figure 24A). We next
treated cells over an extended period and found that upregulation of EpoR after LEN
exposure doubled within 1hr of treatment (Figure 24B), and continued to increase
through 8hr of incubation, showing no significant decay as late as after 24 hours of
drug exposure (Figure 24C, densitometry analysis Figure 24D). To determine
whether EpoR upregulation was transcriptionally mediated, EpoR gene expression
was assessed by real time Q-PCR. We found no change in EpoR mRNA expression
after LEN treatment, indicating that receptor protein upregulation is a post
transcriptional event (Figure 24E). To investigate whether LEN had similar
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Figure 24. LEN increases EpoR expression. (A) Western blot of UT7 cells treated
with increasing concentrations of LEN for 1hr showing a dose-dependent increase in
EpoR expression by the immunomodulatory agent, lenalidomide (LEN). (B)
Densitometry analysis. (C) Western blot of UT7 cells treated with 1µM LEN over the
indicated time intervals showing an increase in EpoR protein expression as early as
1hr with continued increase up unitl 8hr after treatment. (D) Densitometry analysis.
(E) Relative expression of UT7 EpoR mRNA detected by Q-PCR showing no change
in transcription indicating that LEN increases EpoR expression at the protein level.

receptor modulating effects in primary erythroid progenitors, bone marrow
mononuclear cells (BM-MNC) were isolated from three normal donors and changes
in EpoR expression was assessed by quantitative fluorescence microscopy in
erythroid precursors identified by CD71 expression (Figure 25A). We confirmed that
LEN induced a statistically significant increase in EpoR expression in normal,
primary erythroid progenitors after 1h of drug exposure (Figure 25B). Mean
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Figure 25. LEN induces EpoR expression in primary erythroid progenitors. (A)
Representative immunofluorescent micrographs of three primary normal BM-MNC
erythroid progenitors. Erythroid progenitors were identified as CD71+. Dapi (blue),
CD71 (green), EpoR (red), and merged image. (B) Mean fluorescence intensites
(MFI) +/- standard error showing an increase in EpoR expression in erythroid
progenitors after LEN treatment (p=0.003). N=total number of cells analyzed from
all donors.

fluorescent intensity (MFI) of untreated erythroid progenitors was 1043.5 +/- 32.5
(SE) vs 1216.6 +/- 51.7 for cells treated with 1µM LEN for 1 hr (p=0.003).

LEN stabilizes EpoR expression. Our findings that LEN treatment yielded a
sustained cellular increase in EpoR receptor expression suggested that LEN may
act through suppression of receptor turnover. To determine whether LEN increased
the stability of EpoR protein, we first treated cells with cyclohexamide (CHX) to
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inhibit new protein synthesis. UT7 cells were treated with 1µM CHX for 24hr either
with or without LEN (co-treated for 1hr after 24hr CHX pretreatment), and lysates
collected at the indicated time points over a 72hr period. Western blot was
performed to investigate the levels of EpoR at each time point. Treatment of UT7
cells with CHX showed approximately a 50% reduction in EpoR expression at 56hr,
however, addition of LEN markedly extended the half-life of EpoR to beyond 72hr
(Figure 26). These data demonstrate that LEN stabilizes the EpoR protein, to
increase cellular density of signaling competent receptors.

Figure 26. LEN increases EpoR stability. Western blot of UT7 cells treated with
cyclohexamide (CHX) either with or without LEN treatment. Treatment with LEN
increased EpoR stability changing the half-life from approximatley 56hr to out past
72hr.

Cytokine receptor induction by LEN is limited to Type I cytokine
receptors. To determine if the effects of LEN on receptor turnover are restricted to
Type 1 cytokine receptors, we examined the effects of LEN on cellular expression of
IL3-R (Type 1) and c-Kit (Type 2). LEN upregulated IL3-R expression in a
concentration-dependent manner, whereas c-Kit expression was unchanged,
confirming Type 1 receptor specificity (Figure 27).
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Figure 27. LEN increases expression of Type I cytokine receptors. Western blot of
UT7 cells treated with LEN at increasing concentrations and corresponding
densitometry values. LEN increased expression of only Type I receptors (IL3-R and
EpoR) and had no effect on the Type II receptor, c-Kit, confirming specificity to Type
I receptors.

LEN inhibits the E3 ubiquitin ligase activity of RNF41. Recent
investigations have shown that steady state EpoR turnover is regulated through the
E3 ubiquitin ligase, RNF41. RNF41 regulates ligand independent expression levels
of Jak2 associated, Type I cytokine receptors via substrate ubiquitination and
targeted proteasome degradation. We first confirmed that RNF41 bound to
EpoR/Jak2 complexes after LEN treatment by protein immunoprecipitation (IP)
followed by EpoR and Jak2 immunoblot (IB). EpoR:RNF41 binding increased in a
concentration dependent fashion with LEN treatment (Figure 28A). Additionally, IP
of EpoR followed by IB of RNF41 showed similar results (data not shown). To
investigate the effects of LEN on RNF41 function, we assessed protein specific
ubiquitination after proteasomal inhibition with bortezomib followed by LEN treatment.
IP of RNF41 followed by ubiquitin IB showed that LEN inhibited RNF41 auto-
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ubiquitination in a concentration-dependent fashion, therefore mirroring the effects
on receptor:RNF41 association (Figure 28B). Drug inhibition of the E3-ubiquitin
ligase auto-ubiquitination resulted in cellular accumulation of RNF41 expression with
corresponding increased association with EpoR and Jak2 (Figure 28A and C),
paralleling the decrease in EpoR ubiquitination, suggesting that the E3-ubiquitin
ligase inhibitory effects of LEN extends to RNF41 (Figure 28D).

Figure 28. LEN inhibits RNF41 ubiquitin ligase function. (A) Immunoprecipitation
(IP) of RNF41 in UT7 cells treated with LEN at indicated concentrations for 1hr.
There is a dose dependent increase in co-immunoprecipitation of EpoR and Jak2
with RNF41 after LEN treatment. (B) RNF41 was immunoprecipitated then
immunoblotted (IB) for ubiquitin. Bortezomib was used to block proteasomal
degradation. LEN decreases the ubiquitination of RNF41 in a dose dependent
manner. (C) RNF41 protein expression levels increase in total cell lysates of UT7
cells treated with LEN for 1hr at the indicated concentrations corresponding with
decreased RNF41 ubiquitination. (D) Ubiquitination of EpoR decreases with LEN
treatment [(IP) EpoR, (IB) ubiquitin] via inhibition of RNF41 ligase activity.
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RNF41 overexpression abrogates LEN-induced upregulation of EpoR.
To confirm that RNF41 is the principal target of LEN responsible for EpoR
stabilization, we transfected HEK293T cells with EpoR and/or RNF41 expression
vectors using the calcium phosphate method. Steady state EpoR expression
was lower in EpoR/RNF41 cells compared to cells transfected with EpoR alone
(Figure 29). Moreover, EpoR upregulation by LEN was abrogated in
EpoR/RNF41 cells indicating that cellular RNF41 is a critical determinant of EpoR
upregulation by LEN.

Figure 29. Overexpression of RNF41 blocks LEN-induced increase in EpoR
expression. Western blot and corresponding densitometry analysis of UT7 cells
transfected with EpoR (pMET7-EpoR) or EpoR and RNF41 (pMet7-RNF41)
showing a decrease in steady state EpoR, as well as inhibition of LEN-induced
EpoR, with RNF41 overexpression.
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RNF41 expression is decreased in LEN responsive MDS primary
erythroid cells. To determine the effects of LEN on RNF41 expression in vivo, we
performed immunohistochemistry on 18 (6 LEN responders, and 12 non-responders)
bone marrow biopsies from non-del(5q) MDS patients and stained for RNF41 and
the erythroid marker spectrin (Figure 30A). By assessing cellular expression profiles
in bone marrow biopsies obtained before and after LEN treatment, we were able to
assess the relationship between cellular RNF41 level in erythroid precursors and
clinical erythroid response. Relative expression of RNF41 in erythroid precursors at
baseline was lower in responding patients (non-responder = 0.47 ± 0.03, responder
= 0.43 ± 0.07, p=0.07) (Figure 30B). Furthermore, the relative reduction in cellular
RNF41 expression in erythroids was significantly greater in responding patients
compared to non-responders (non-responder = 1.06 ± 0.09, responder = 1.11 ± 0.22,
p=0.05) (Figure 30C). These results, if validated in a larger data set, suggest that
cellular RNF41 expression level in erythroid precursors may serve as a predictive
biomarker for LEN response in MDS. Moreover, the ability of LEN to reduce
expression in responding patients may be an important biological marker of
therapeutic efficacy. It should be noted that in our in vitro studies, expression of
RNF41 decreased after 1hr of LEN exposure, however, in our IHC experiments,
RNF41 levels decreased after extended drug exposure. As our IHC RNF41
antibody is reactive to only a small portion of the C-terminus of the protein, it is
possible that the reactive site may be masked due to binding of RNF41 to other
proteins, such as Jak2 or EpoR, and should be confirmed with an additional antibody.
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Figure 30.
RNF41 expression decreases in MDS LEN responders.
(A)
Representative immunohistochemical analysis of MDS bone marrow biopsies.
RNF41 is shown in brown and spectrin for erythroid identification is shown in red.
The relative expression of RNF41 is increased in LEN non-responders (B) and the
relative reduction ratio significantly decreased in LEN responding patients (p=0.05)
(C) Furthermore, marked increases of spectrin (red) were observed in responding
patients (top IHC panel), whereas there was either no change or a decreases in
spectrin staining in non-responders (bottom IHC panels).

Discussion
Our investigations have shown that LEN upregulates the expression of
signaling competent Jak2 associated receptor complexes in a concentrationdependent manner, and that EpoR upregulation is a post-transcriptional event
yielding accumulation of signaling competent JAK2/EpoR complexes primed to
augment Epo response. Inhibition of the E3 ubiquitin ligase activity of RNF41
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increases EpoR stability and is responsible for LEN induced upregulation of the
receptor, given that forced overexpression of RNF41 inhibits receptor upregulation.
Furthermore, cellular expression of RNF41 in bone marrow erythroid precursors in
patients who responded to LEN treatment was lower as assessed by
immunohistochemistry. Moreover, the relative ratio of RNF41 expression
significantly decreased in responding patients compared to non-responders (p=0.05).
These data suggest that RNF41 expression in erythroid precursors may be a useful
biomarker predictive for response to LEN and merits further investigation in a larger
patient cohort.
Our data support the recent findings of LEN inhibition of E3 ligase complexes,
including cereblon and MDM2.39,168,169,175 Collectively, these data suggest that LEN
may act as a much broader RING finger E3-ubiquitin ligase inhibitor than originally
appreciated. The study of LEN on E3 ligase inhibition should be extended to include
more proteins including the other major family of ligases, the HECT ligases, since
direct binding sites of the IMiDs have yet to be clearly determined. It is possible that
LEN may be inhibiting ligase function via alteration of the ligase complex or binding
to the E2 components, and therefore, may not be specific to the RING ligases. Rac
GTPases responsible for actin cytoskeletal reorganization and plasma membrane
compartmentalization, are activated by IMiDs, however, the mechanism is not known.
Perhaps inhibition of specific ligases that ubiquitinate these GTPases underlies the
drug activating effects. Furthermore, E3 ligases are important for cellular transport
and inhibition by LEN may have a profound effect on the spatial organization of
cellular machinery.162 Additionally, E3 ubiquitin ligases are important for chromatin
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remodeling and LEN inhibition on these proteins may have significant effects on
gene expression.201 Recently, the E3 ubiquitin ligase SMURF2 (Smad ubiquitin
regulating factor 2) was shown to regulate histone 2B (H2B) ubiquitination, and
consequently methylation, through inhibition of the RING finger ligase, RNF20.201
Perhaps LEN inhibits RNF20 to directly alter expression of erythroid differentiation
genes, or in turn, may inhibit SMURF2 effecting RNF20 expression and gene
transcription. As these suggestions are speculative, investigations of more ligases
(both RING domain and HECT) are warranted, and will provide further insights into
the molecular mechanisms of this immunomodulatory agent.

Methods

Reagents and Cells. UT7 cells were grown in alpha-MEM with 20% FBS,
1 % penicillin/streptomycin solution, and 5 ng/ml GM-CSF. HEK-293T cells were
maintained in DMEM supplemented with 10% FBS. Normal bone marrow
mononuclear cells were purchased from Lonza Walkersville (Walkersville, MD)
LEN was purchased from Fisher Scientific (Pittsburgh, PA). Ubiquitin, IL3-R, cKit, and CD71 antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). β-Actin antibody was purchased from Sigma Aldrich (St. Louis, MO).
EpoR and RNF41 antibodies were purchased from Abcam (Cambridge, MA).
Cyclohexamide was purchased from Sigma Aldrich (St. Louis, MO) Bortezomib
was purchased from (Sellechchem, Houston, TX).
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Western blotting. Cells were treated as indicated then harvested and
lysed in 1X RIPA buffer with 250µM NaOV4, 2µg/mL aprotinin, 2µg/mL leupeptin,
0.2µg/mL pepstatin A, and 500µM PMSF. Proteins were resolved by SDS-PAGE
and transferred to PVDF membranes. Membranes were blocked in 5% dry milk
PBST solution (PBS with 0.1% Triton X) and incubated with the indicated
antibody. Membranes were washed and developed using ECL or ECL+
according to manufacturer’s protocol.

Quantitative PCR. RNA was isolated from UT7 cells using the RNeasy
Mini Kit (Qiagen, Valencia, CA) cDNA was generated using High Capcity cDNA
Reverse Transcription Kit (Life Technology, Applied Biosystems, Foster City, CA)
per protocol. ActB and 18S RNA was used as endogenous controls. EpoR, 18S,
and ActB mRNA was detected using TaqMan® Gene Expression Assays (Life
Technology, Applied Biosystems, Foster City, CA). Real time PCR was carried
out on an ABI PRISM 7900HT Sequence Detection System with triplicate
samples using TaqMan® Universal PCR Master Mix with 2 min incubation at
50°C, then activation of AmpliTaq Gold for 10 min a t 95°C, then 40 cycles of 15s
at 95°C and 1min at 60°C. Data was analyzed using SDS software (v2.3) EpoR
mRNA was normalized to endogenous controls.

Immunoprecipitation. Two hundred micrograms of protein from total cell
lysates were incubated with 2µg of indicated antibody for 2h on ice. Fifty
microliters of Protein G Agarose beads (EMD Millipore, Billerica, MA) were added
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and incubated overnight on a rotator at 4°C. Bead- lysate slurries were washed
3x in lysis buffer. Sample buffer was then added, and beads were dissociated at
95°C for 5 min. Proteins were separated by SDS-PAG E and immunoblotted with
indicated antibodies.

Immunofluorescence. BM-MNC were treated with 1µM LEN for 1 hr.
The cells were then cytospun for 5 min at 450rpm. Slides were fixed in BD
cytofix for 10 minutes at 37°C for 10min, washed wi th PBS, then blocked in
2%BSA/PBS for 5min at room temperature (RT). Cells were then incubated with
primary antibody (1:50 for EpoR and 1:200 for CD71) for 1hr at RT, washed, and
incubated in secondary antibody (1:1000) for 1hr at RT. Cells were washed
again, DAPI was added, and a cover slip placed on. Micrographs were taken
using a Leica TCS SP5 AOBS Laser Scanning Confocal microscope (Leica
Microsystems, Germany). Data was analyzed using Image Pro Plus version 6.2
(Media Cybernetics, Inc., Silver Springs, Maryland).

Transfections. HEK-293T cells were transfected using the calciumphosphate method using pMET7/EpoR and pMET7/RNF41 expression vectors
kindly provided by Dr. Jan Tavernier from Ghent University (Ghent, Belgium).
Briefly, cells were transfected with 2µg DNA by the calcium phosphate method.
Three hours after transfection, medium was changed. Cells were either
harvested for expression detection or treated after 48hr.
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Immunohistochemistry. Paraffin embedded bone marrow core biopsies
were deparaffinized using EZ prep solution (Ventana Medical System, Inc, Oro
Valley, AZ). Slides were stained sequentially, first with prediluted spectrin (Cell
Marque, Rocklin, CA) for 16min followed by secondary for 8min, and was
demonstrated with red chromagen. RNF41 secondary antibody (Abcam,
ab84409) was added (1:400) for 60 min, with secondary incubation of 16min, and
detection by 3,3' Diaminobenzidine (DAB) chromogen. Retrieval was done with
cell conditioning 1 (Ventana Medical Systems, Inc.) Slides were dehydrated and
cover-slipped for analysis. Slides were scanned using AperioTM (Vista, CA)
ScanScope XT with a 200x/0.8NA objective lens via tri-liner-array. Three regions
from each slide were manually selected by the study pathologist and extracted
without compression into Definiens Tissue Studio v3.0 software suite for
quantitative analysis. These regional images were segmented using Tissue
Composer to classify co-localized regions of interest using the red spectrin
staining as the initial nuclear detection marker. The cells of interest were
spectrin positive erythroid cells which also displayed RNF41 staining. Therefore,
each nucleus within the regions of interest was identified with a hematoxylin
threshold of 0.16 and an IHC threshold of 1. Cytoplasms were grown from the
nuclei and thresholded into weak, moderate and strong intensity (0.15, 0.28, 0.55,
respectively). This complete solution enabled the number of RNF41 positive
erythroid cells (colocalized staining) to be identified as well as the mean RNF41
intensity in spectrin positive cells. Segmented based on the intensity of the
staining of the various markers, in both nuclear and cytoplasmic areas, where
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applicable, and classified as erythroid cells within the region of interest based on
the mean intensity of that cellular object. The training algorithm was closely
monitored by the study pathologists and applied to all images representative of
the patients’ slides.
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CHAPTER 5
Discussion

Summary
In the investigations presented here, we have shown that plasma
membrane lipid raft microdomains are deficient in MDS, and that EpoR signal
fidelity is dependent upon its localization within membrane raft fractions
(Chapters 2 and 3). We first showed that Epo stimulation induces raft
aggregation and the recruitment of EpoR with the signaling effectors Jak2,
STAT5, and Lyn kinase, while CD45, a tyrosine phosphatase negative regulator
of the growth factor signal, was sequestered outside of raft fractions. Disruption
of lipid rafts abrogated Epo signaling, thereby emphasizing the importance of
lipid raft integrity for EpoR signal competence. Our subsequent investigations
identified two mechanisms by which LEN can augment EpoR signaling in MDS,
1) through promoting the assembly of lipid rafts and their obligatory signaling
constituents, and 2) EpoR up-regulation. We showed that LEN induced the
formation of lipid rafts accompanied by recruitment of EpoR, Jak2, and STAT5,
while re-partitioning CD45 largely to non-raft fractions independent of ligand
engagement (Chapter 3). Induction of raft formation by LEN, and recruitment of
EpoR by rhEpo, was dependent upon the activity of Rho and Rac GTPases,
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through regulation of F-actin polymerization and cytoskeletal reorganization
(Figures 18, 21, and 22). These findings demonstrate the importance of
GTPases in LEN’s erythropoietic promoting effects. GTPases are important
regulators of hematopoiesis, and their activation by LEN has important
consequences, not only on EpoR signal fidelity, but also on erythroid survival as
supported by our prior data showing enhancement of colony-forming capacity.160
F-actin polymerization triggered by the activation of GTPases by LEN is a key
effector mechanism regulating lipid raft assembly and aggregation. However, the
importance of cytoskeletal reorganization prefacing raft assembly warrants
discussion. Expression of DOCK4, a gene integral to cytoskeletal regulation is
decreased in MDS compared to normal progenitors, and is associated with
decreased F-actin polymerization, increased erythroid fragility, and
apoptosis.202,203 LEN’s induction of actin cytoskeletal reorganization likely plays
an important role in enhancing erythroid viability, in addition to priming
progenitors to augment EpoR signal fidelity by inducing the formation of raft
signaling platforms, thereby contributing to erythropoietic rescue in responding
MDS patients.
The second mechanism by which LEN may augment EpoR signaling is
through upregulation of EpoR. We demonstrated that LEN increases EpoR
expression through inhibition of the E3 ubiquitin ligase activity of RNF41 (Chapter
4). LEN inhibits both the auto-ubiquitination of RNF41, and RNF41’s
ubiquitination of EpoR, thereby increasing receptor stability. Decreased
degradation of the Jak2/receptor complex should enhance signaling by
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increasing the number of receptors available for membrane translocation and
ligand binding. Although erythroid progenitors from MDS patients display
comparable levels of surface receptors compared to healthy individuals, lipid
rafts are decreased, which compromises EpoR signal competence. Moreover,
an increase in RNF41 would promote Type I receptor degradation, which could
decrease the number of internalized receptors available for recycling to the
plasma membrane after growth factor stimulation, thus decreasing the duration of
Epo induced stimulation. Furthermore, we found that erythroid expression levels
of RNF41 prior to treatment with LEN in non-del(5q) MDS responding patients
was lower than that found in non-responders, whereas the relative reduction ratio
after treatment was greater in responders than in non-responders (Figure 30),
suggesting greater receptor stability and Epo responsiveness in responding
patients. These results also suggest that RNF41 might serve as a potential
biomarker predictive for LEN responsiveness in non-del(5q) MDS.
In summary we have shown two mechanisms by which LEN enhances
EpoR signaling, 1) through induction of lipid raft assembly accompanied by
recruitment of the receptor and signal effectors, and 2) through increased protein
expression and stability of EpoR. Collectively, these mechanisms serve to
address primary disturbances in membrane raft/cytokine receptor signaling in
MDS. LEN promotes lipid raft assembly, rescues ineffective erythropoiesis, and
enhances Epo/STAT5 signaling and progenitor survival to correct anemia in
LEN-responsive MDS patients. In support of this, the French MDS Group
recently reported the results of a randomized clinical trial comparing erythroid
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hematologic response to treatment with LEN alone vs. LEN and epoetin beta in
transfusion dependent patients with non-del(5q) MDS previously unresponsive to
Epo treatment. The results of this study showed that the combined treatment
significantly improved erythroid response and frequency of transfusion
independence (23% vs. 40%; p = 0.04) (Abstract #7002, 2013 ASCO Annual
Meeting, Chicago, IL). Moreover, recent studies implicate allelic deletion or
mutation of genes involved in GTPase/cytoskeletal regulation in the
pathogenesis of MDS. Examples of this include RhoB, mDia, and Smap1.
Smap1 is an ARF6 GTPase-activating protein, and loss of the gene causes a
myelodysplastic phenotype in mice, as well as AML development.204 Loss of
either RhoB GTPase or its effector, mDIA, similarly causes myelodysplastic
phenotypes in mice.155,156 These data suggest that novel strategies that promote
stimulation of Rho or Rac GTPase activation may address a critical abnormality
in cytokine signaling in MDS.

Future Studies
There are a number of additional studies that are warranted to delineate
precise disturbances in raft assembly in MDS, GTPase activity and the
mechanism(s) by which LEN activates GTPases to effect cytoskeletal changes.
First, although we and others have shown that the GTPases induce actin
cytoskeleton reorganization resulting in increased raft or synaptosome formation,
the specific targets involved in this process are unknown. Identifying key
regulatory components in cytoskeletal dynamics could support pharmacologic
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strategies for development of novel hematopoietic promoting agents. A summary
of possible mechanisms involved in the deregulation of the actin cytoskeleton
that may contribute to the pathogenesis of MDS is provided in Figure 31.
Currently, there are three GTPases known to regulate the actin cytoskeleton,
RhoA, Rac1, and Cdc42. Although RhoA and Rac1 are activated within minutes
of LEN treatment, the same response is not observed for Cdc42.128 In our
studies we showed abrogation of LEN induced F-action polymerization by
pretreatment with a Rac1 inhibitor, and recruitment of EpoR into raft fractions
was abrogated by both a Rac and ROCK inhibitor, however, the specificity of
these inhibitors is insufficient to determine the precise GTPases (or GEFs)
involved, or, whether there are any overlapping functions, or compensatory
mechanisms. To address this, additional investigations with knockdown of
specific proteins are needed. Although there are 20 Rho family GTPases and
more than 150 Rac superfamily GTPases, one could begin with the Rac like Rho
GTPases (Rac1, 2, and 3) known to be heavily involved in hematopoiesis, and
the Rho-like GTPases (RhoA, B, and C), which are known to be involved in
cytoskeletal regulation. Furthermore, to confirm that F-actin polymerization is
required for lipid raft formation, cells should be treated with a polymerization
inhibitor in combination with LEN, however, since F-actin polymerization
inhibitors are extremely cytotoxic, caution should be used in interpreting results
from such studies.
We speculate that GTPase activation by LEN may occur through E3
ubiquitin ligase inhibition, and therefore, after identification of the specific
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Figure 31. Cytoskeletal deregulation in MDS. Deregulation of the actin
cytoskeleton may occur via a number of different mechanisms including loss of
Rho GTPase activity, deregulation of DOCK4 by hypermethylation, mutation, or
deletion, increase in E3 ligase activity resulting in Rho GTPase proteasomal
degradation, inhibition of either the Rho GTPases and/or Rho kinase, ROCK, by
micro RNAs, loss of the formin family protein, mDia as in del(5q) MDS, or
through the Rho regulatory phosphatase, PP2A, which is inhibited by LEN.

GTPases involved in raft formation, targeting ligases responsible for their
degradation should follow. At present, there are only three known ligases for
Rho family GTPases (SMURF, Cul3, and HACE1). Of these, only Cul3 is a
RING domain ligase. Currently, LEN’s ligase inhibitory activity is known to
extend only to three RING domain ligases (cereblon, MDM2, and RNF41),
however, the effects of LEN on the HECT ligases should also be investigated. At
present, there is only one study suggesting a possible IMiD binding site to CRBN
(and no data on the binding sites for MDM2 and RNF41, investigations that we
are currently pursuing), and that site is at the C-terminus of the protein.169
However, this determination was based solely on site specific point mutations at
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amino acids 384 and 386, and decreased inhibition of ligase activity by
thalidomide. Direct interactions have yet to be validated, and therefore it is
possible that ligase inhibition may not be specific to RING domain ligases.
Perhaps, LEN is a broad E3 ligase inhibitor with effects on all ligases. This
would particularly hold true for the pseudo-RING/HECT hybrid ligases, which
have characteristics of both the RING and HECT ligases. Until the direct binding
sites of the IMiDs and E3 ligases are determined, the possibility for broad ligase
inhibition should not be discounted. Currently, high throughput E3 ligase
screening assays are available, and these may be utilized to determine whether
LEN specific ligase inhibition leads to GTPase activation.205
Additionally, the question of whether lipid rafts are responsible for the
recruitment and aggregation of EpoR and signaling effectors, or, whether these
processes are dependent on the receptor itself, merits further investigation. We
are currently investigating whether knockdown of EpoR alters LEN’s ability to
induce membrane raft assembly to determine if receptor expression is necessary
for raft induction. Furthermore, since the cereblon complex was the first
identified target of the IMiDs, the role of cereblon should also be investigated to
determine its role, if any, in LEN’s promoting effect on raft aggregation and Factin polymerization. Studies utilizing lentivirus knockdown of cereblon are
underway.
Another important follow up study should validate the potential of an
erythroid RNF41 score as a biomarker for response to LEN in non-del(5q) MDS.
In our preliminary studies, IHC studies were performed on bone marrow biopsy
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sections from 6 patients who responded to LEN treatment and 12 nonresponders. Erythroid precursors were identified using the erythroid marker,
spectrin. We found decreased baseline expression of RNF41 in the erythroid
progenitors of responders compared to non-responders that approached
statistical significance (p=0.07). We suspect that by increasing the number of
patients studied, we may obtain statistically significant results. Furthermore, we
found that the magnitude of reduction in erythroid RNF41 expression with LEN
treatment (relative reduction ratio) was greater in responding patients than in
non-responders, further emphasizing the importance of RNF41 in the response
to LEN treatment. LEN’s ability to downregulate RNF41 may be an important
determinant of the compound’s ability to restore effective erythropoiesis. In our
in vitro studies, treatment with LEN increased RNF41 protein expression after 1hr
of treatment by inhibiting its autoubiquitination. However, our IHC results
showed that long term LEN treatment in LEN-responsive MDS bone marrow
biopsies resulted in a decrease in expression in erythroid progenitors of
responding patients. The antibody used for IHC recognizes the C-terminus
residues 275-317 on RNF41, whereas the antibody used for western
immunoblots and IP was raised against the full length RNF41, therefore, it is
possible that the decrease in RNF41 after extended LEN exposure was due to
masking of the reactive site. Alternatively extended drug exposure may have
different biological effects that were not explored in our preclinical studies. To
address this, UT7 cells should be treated daily with LEN over an extended period
of time to determine the long term effect of LEN on RNF41 in vitro. Additionally,
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an alternative RNF41 antibody could be used for IHC staining of bone marrow
specimens that recognizes a different binding region and/or reactivity to the full
length protein to confirm the observed reduction in expression after long term
treatment. Furthermore, we should determine whether EpoR expression
increased in erythroid precursors in LEN-responsive MDS patients as a
consequence of RNF41 inhibition, and its relationship to changes in RNF41
levels. Lastly, we should determine whether RNF41 expression is increased in
MDS patients compared to normal controls, as this may provide insight into
disease biology.
Previous studies have shown that plasma membrane raft density is
decreased in stimulated neutrophils from MDS patients.198,206 In our studies, we
show that lipid raft density is also decreased in MDS bone marrow erythroid
progenitors, but that lipid raft assembly can be augmented, and all components
of the EpoR signaling axis can be aligned within lipid rafts through pharmacologic
stimulation of the cytoskeleton. The biological abnormalities underlying the
deficiency in raft assembly in MDS warrants further investigation. Although
decreased DOCK4 expression represents one mechanism, additional studies
should explore whether there is an inherent decrease in Rho GTPase activity in
MDS stem and progenitor cells resulting in decreased F-actin polymerization and
lipid raft formation. DOCK4 is located at 7q31 and may be regulated through
promoter methylation, mutation, or deletion.202,203,207 Interestingly, chromosomal
abnormalities at this position are associated with poor prognosis in both MDS
and AML.208 This could account for ineffective cytokine signaling platforms,
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decreased EpoR signal fidelity, and decreased erythroid progenitor differentiation
and proliferation. As the actin cytoskeleton is closely controlled by the GTPases,
a deficiency in GTPase activation in MDS progenitors could result in ineffective
erythropoiesis. This notion is supported by finding that MDS neutrophils have
decreased Rac activation and decreased F-actin integrity associated with
decreased DOCK4 expression, as well as evidence of myelodysplasia resulting
from GTPase and associated protein knockdown.206 Alternatively, mDIA, the
Rho GTPase effector, is another possible deregulated protein of the cytoskeleton,
possibly contributing to myeodysplasia.142 The mDIA gene is located at 5q31.3,
the location of the commonly deleted region in del(5q) MDS, and loss of mDia in
a mouse model resulted in a myelodysplastic phenotype.155,156 Furthermore, it
would be of interest to compare lipid raft integrity and aggregation in non-del(5q)
MDS LEN responders vs non-responders to determine if raft density or dynamics
in response to drug exposure could serve as a biomarker for drug
responsiveness. One would expect that lipid rafts may be decreased in LEN
responders, and that one mechanism by which therapeutic efficacy is achieved is
through rescue of diminished raft density as suggested in Figure 23. Another
mechanism by which lipid rafts may be diminished in MDS patients is through
defects in raft manufacturing. The processing of sphingolipids and cholesterol
with respect to raft manufacturing in MDS patients should be investigated.
Defects in either the machinery and/or the translocation of raft components may
account for the decreased raft density observed in these patients. This
hypothesis is supported by decreased expression of an array of genes involved
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in lipid metabolism in MDS patients.209 Additionally, MDS patients have reported
decreased levels of serum cholesterol, low-density lipoproteins (LDL), and highdensity lipoproteins (HDL); and the mechanisms responsible for these could
similarly be responsible for the deficiencies in raft density.210 Although, since
induction of rafts by LEN occurs within 1hr, there is likely not a defect in
cholesterol synthesis suggesting alternative mechanisms. A more likely
hypothesis is that there are alterations in the distribution of raft components, and
that this is associated with F-actin polymerization and the cytoskeleton. It is well
established that in acute myeloid leukemia (AML), there is high cholesterol
content in blast cell plasma membranes.211,212 This suggests that there may be
less available circulating cholesterol available for raft formation and stabilization.
Furthermore, a change in F-actin polymerization induced by activation of the
GTPases after LEN treatment could quickly redistribute these molecules to
create functioning lipid rafts. Another mechanism by which LEN may upregulate
the GTPases to induce F-actin polymerization is through inhibition of PP2A. Our
laboratory showed that selective cytotoxicity of del(5q) MDS clones by LEN was
accomplished through inhibition of the regulatory phosphatases, PP2A and
Cdc25c.51 Rac GTPases, and actin depolymerizing protein, cofilin, are known
targets of PP2A, inhibition of the phosphatase has been reported to upregulate
the GTPases and induce F-actin polymerization.213-215 Our laboratory has
performed preliminary experiments supporting this hypothesis that are depicted
in Figure 32. UT7 cells treated with the PP2A inhibitor, cantharadin, showed an
increase in F-actin polymerization determined by immunofluorescence, an
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Figure 32. The PP2A inhibitor, cantharadin, induces F-actin polymerization and
lipid raft formation. (A) F-actin polymerization is induced by cantharadin.
DAPI=blue, F-actin=green. (B) GM-1 dot blot of UT7 cells either stimulated with
Epo or treated with cantharadin showing an increase in raft fractions (1 and 2).
(C) Western blot of isolated fractions showing increasing Lyn fractionation with
GM-1 after cantharadin treatment.

increase in lipid raft fractionation detected by GM-1 dot blot, and increased Lyn
fractionation to the raft domains. However, to validate that PP2A inhibition by
LEN induced F-actin polymerization through activation of GTPases, gene
transfected cells lines and appropriate controls should be utilized. Lastly, the
cytoskeleton is regulated by microRNAs (miRs) (Figure 31).216 Both the
GTPases and ROCK are regulated through miRs that potentially may be
deregulated in MDS. Some miRs known to regulate the Rho GTPases include
miR-31, 133, 155, and 185.217-220 In fact, miR-155 is identified to be upregulated
in MDS CD34+ cells compared to normal counterparts.221 Additionally, the miRs138, 184, and 205 are known down-regulators of the Rho kinase, ROCK.222,223
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Investigation of the role of these miRs in the context of MDS and activation of
GTPases resulting in cytoskeletal reorganization is warranted. Ultimately, the
studies suggested here will provide valuable insight into the disease biology of
non-del(5q) MDS, as well as the abnormalities underlying impaired raft assembly
in MDS, thereby offering opportunities for development of novel therapeutics for
the treatment of patients with MDS.

Implications
The implications of the findings presented here extend not only to the
molecular mechanisms of LEN, and the disease biology of MDS, but also to
potential biomarkers and novel therapeutic strategies. For example, we propose
that RNF41 expression may be used as a biomarker predictive for LEN response
for MDS patients. Currently, only about 25% of non-del(5q) MDS patients
experience a hematologic response to LEN monotherapy, therefore an accurate
biomarker could significantly improve selection of patients most likely to benefit
as well as time and cost savings. Furthermore, lipid raft density and raft
induction by LEN may be used as markers for response, providing further means
for patient selection. Those patients with relatively normal levels of rafts and/or
low induction of raft aggregation, may be less likely to respond to LEN compared
to those who have decreased levels of raft density. Furthermore, if the
mechanism by which rafts are decreased in MDS can be identified, these
alterations as well, may provide novel therapeutic targets. These studies would
require validation in a prospective treatment trial.
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Additionally, small molecules could be used to inhibit the activity of E3
ubiquitin ligases. For example, inhibition of RNF41 would lead to an increase in
expression of EpoR and other Type I cytokines, whereas inhibition of the ligases
responsible for the degradation of GTPases could induce F-actin polymerization.
Specific E3 ligase inhibitors would limit the number of off-target effects that would
be expected from using a broad E3 ligase inhibitor. Furthermore, if we could
determine alternative methods for activating the GTPases, i.e., by activating
GTPases activating proteins (or GAPs), or promoting F-actin polymerization,
these methods may be useful in restoring effective erythropoiesis in MDS.
Ultimately, as we gain both disease and drug knowledge, prognosis of
patients diagnosed with MDS, and other hematologic malignancies, should prove
to be more promising.
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